Archive May

Archive for May, 2014

(OHRP) Announces Agreement to Acquire Technology Assets of SKS Ocular

Transaction Expands Ohr’s Pipeline to Include Multiple New Drug Candidates in Ophthalmology
Provides Ohr with Proprietary Sustained Release Drug Delivery Platform for Ocular Drugs
Upfront Purchase Price Payment of $3.5 Million in Cash, 1,194,682 shares of Ohr Common Stock Plus Contingent Development Milestones
Drs. Jason S. Slakter, Glenn L. Stoller and Peter K. Kaiser to Join Ohr Management Team
Conference call today at 5:00 pm Eastern/2:00 pm Pacific

NEW YORK, May 15, 2014 — Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has entered into a definitive agreement with privately held SKS Ocular LLC and its affiliate SKS Ocular 1 LLC (“SKS Ocular”) to acquire SKS Ocular’s ophthalmology assets. The transaction will provide Ohr Pharmaceutical with a proprietary, patent protected, sustained release technology platform under development as well as a pipeline of pre-clinical sustained release drug product candidates that address unmet medical needs in glaucoma, retinal disease and other ophthalmic indications. The lead development program is currently being pursued under a research collaboration with a large global pharmaceutical company. As part of the agreement, Ohr will also gain a strong research and development team and a state of the art research laboratory in San Diego, CA. The transaction is expected to close by the end of May.

Under the terms of the agreement, in exchange for substantially all the assets of SKS Ocular, Ohr will make an upfront payment of $3.5 million in cash and 1,194,862 shares of Ohr common stock. In addition, SKS Ocular will be eligible to receive up to 1,493,578 additional shares of Ohr common stock in contingent milestone payments. These payments will be made if the acquired platform and pipeline drug candidates are successful in meeting certain specified development and regulatory goals within a specified time frame. SKS Ocular will also be entitled to receive a portion of any cash payments to Ohr from further collaboration with the large global pharmaceutical company on the lead development program, up to a maximum of $5 million.

SKS Ocular is a biopharmaceutical company that is developing a sustained release technology platform to develop best-in-class drug formulations for ocular disease. The SKS Ocular sustained release technology contributed to Ohr employs micro fabrication techniques to create nano and microparticle drug formulations that can provide sustained and predictable release of a therapeutic drug over a 3 – 6 month period. There are four active pipeline programs underway in glaucoma, steroid induced glaucoma, allergic conjunctivitis and protein delivery. The technology was designed to circumvent many of the challenges associated with current drug delivery technologies to deliver drugs including small molecules and biologics for extended durations. It can be applied via multiple ocular delivery routes.

“We are very excited to be acquiring SKS Ocular’s technology, which we see as complementary to our efforts to develop and commercialize Squalamine Eye Drops for retinal disease,” stated Dr. Irach Taraporewala, Chief Executive Officer of Ohr Pharmaceutical. “This acquisition is a continuation of our strategy to build out a robust pipeline with novel, innovative delivery technologies. Our expanded pipeline now includes both early and late stage clinical assets that address multi-billion dollar market opportunities for retinal disease, glaucoma, and other ocular indications.”

“Our decision to join Ohr has been driven both by our conviction of their ability to leverage our technology platform and also by the high value we see in the Squalamine eye drop program,” stated Dr. Jason Slakter, cofounder of SKS Ocular and upon closing, the Chief Medical Officer of Ohr Pharmaceutical. “We look forward to taking an active role in managing the Squalamine clinical trials, in addition to advancing the pipeline of drug candidates we created. We are very pleased to become part of a company that shares our commitment to improving the lives of patients suffering from ocular disease.”

Additions to Management

On closing of the transaction, three of the cofounders of SKS Ocular will be appointed to senior management positions at Ohr Pharmaceutical. Drs. Jason S. Slakter and Glenn L. Stoller will be appointed to the newly created positions of Chief Medical Officer and Chief Scientific Officer at Ohr, respectively. Dr. Slakter is also expected to join Ohr’s Board of Directors in the near future. Dr. Peter K. Kaiser, third cofounder of SKS Ocular, will serve as Senior Vice President of Product Development. “As cofounders and senior managers at SKS Ocular, Drs. Slakter, Stoller, and Kaiser have built a strong pipeline of pre-clinical drug candidates to treat ophthalmic indications,” said Dr. Taraporewala. “In addition to being well respected physicians, they each have extensive experience in the development, regulatory approval and commercialization of pharmaceutical products to treat eye diseases.”

Glaucoma Lead Development Program

SKS Ocular has an ongoing collaboration with a large global pharmaceutical company to develop a new formulation of a therapeutic agent that allows for a 3-month release profile following a single administration into the subconjuctival space. If successful, this approach could potentially result in a significant improvement in glaucoma treatment where the current standard of care is frequent topical, patient administered medications. It has been well established from multiple studies that the single greatest reason for treatment failure in glaucoma today is lack of compliance with medication due to the nature of the disease. Unlike retinal disease where patients, due to clearly evident visual symptoms and vision loss, are highly motivated to be compliant with therapy, glaucoma is typically asymptomatic until late in the disease process and thus compliance is a significant issue. A physician administered drug with a requirement for injections at intervals of several months would greatly improve patient compliance and could have a significant impact on reducing loss of vision from glaucoma.

Additional Programs

The SKS Ocular pipeline also includes sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, including steroid induced glaucoma, allergies, and retinal disease. These indications represent unmet medical needs in ophthalmology and have the potential to fundamentally alter the current market and change the treatment paradigm for ocular disorders.

SKS Ocular’s Drug Delivery Platform

The SKS Ocular sustained release technology employs a hydrogel template approach to prepare nano or microparticles of predeﬁned size and shape and with homogeneous size distribution. The size of the particles can be adjusted, providing ﬂexibility in controlling the size and release rate in drug delivery formulations. The drug loading capacity is much higher than that achieved by conventional methods (30% or higher), with a controlled initial burst release of drug that is minimal. Simplicity in processing makes the hydrogel template method useful for scale-up manufacturing of particles. The technology has significant advantages over currently available microparticle drug delivery systems prepared by emulsion methods. The limits of emulsion technology include low drug loading capacity (usually much less than 10% of the total weight) and often signiﬁcant initial burst release of a drug. This technology platform is adaptable to multiple routes of ocular delivery.

Conference Call & Webcast

Thursday, May 15, 2014 @ 5 pm Eastern Time / 2 pm Pacific Time

Domestic:	877-407-0789
International:	201-689-8562
Webcast:	“Investor Relations” page of www.ohrpharmaceutical.com

Replays available until May 29, 2014
Domestic:	877-870-5176
International:	858-384-5517
Replay PIN:	13582752

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Inc. (OHRP) is a research and development company with a primary focus in ophthalmology. The Company’s lead product, Squalamine, is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase 2 clinical trials for various back-of-the-eye diseases, including the wet form of age related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. Ohr is also developing OHR/AVR118 for the treatment of cancer cachexia. Additional information on the Company can be found at found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:  This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr’s most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

CONTACT: Ohr Pharmaceutical Inc.
         Investor Relations
         (877) 215-4813
         ir@ohrpharmaceutical.com

         LifeSci Advisors, LLC
         Michael Rice
         646-597-6987
         mrice@lifesciadvisors.com

Thursday, May 15th, 2014 Uncategorized Comments Off

(ZIXI) Google and Zix Strengthen Secure Email Protection

Zix Corporation (ZixCorp), (NASDAQ: ZIXI), a leader in email data protection, announces the launch of Google Apps Message Encryption (GAME). GAME is specifically designed by ZixCorp at the request of Google for the Google Apps infrastructure and provides secure email to Google Apps users when communicating outside Google’s secure cloud to all other email users.

Currently Google supports secure email within its infrastructure and between its customers. However, emails sent to users on other email systems such as Yahoo and Microsoft Exchange are vulnerable as they traverse the public Internet. GAME allows encryption of email to every possible recipient, giving Google Apps customers the confidence that they are protecting the sensitive information of their customers and partners.

GAME is commercially available for Google Apps customers through the Google sales team and incorporates Zix^TM Email Encryption capabilities to transmit email securely. ZixCorp is recognized as the industry leader in email encryption by offering innovative, easy to use solutions. To learn more about GAME, read the Message Encryption Quick Start Guide.

“In the midst of growing awareness regarding data threats, it’s more important than ever that companies have a reliable solution for the secure exchange of valuable customer and corporate data,” said Rick Spurr, ZixCorp’s Chairman and Chief Executive Officer. “This announcement enhances the Google Apps offering to provide an end-to-end secure solution for email and is a reflection of our companies’ commitment to the broad-based proliferation of email data protection.”

About Zix Corporation

ZixCorp is a leader in email data protection. ZixCorp offers industry-leading email encryption, a unique email DLP solution and an innovative email BYOD solution to meet your company’s data protection and compliance needs. ZixCorp is trusted by the nation’s most influential institutions in healthcare, finance and government for easy to use secure email solutions. ZixCorp is publicly traded on the Nasdaq Global Market under the symbol ZIXI, and its headquarters are in Dallas, Texas. For more information, visit www.zixcorp.com.

Thursday, May 15th, 2014 Uncategorized Comments Off

(SMLR) Appoints Healthcare Tech Expert Wayne T. Pan, M.D., Ph.D., to Board

PORTLAND, Ore., May 14, 2014 — Semler Scientific, Inc. (Nasdaq: SMLR; “Semler”), an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the appointment of Wayne T. Pan, M.D., Ph.D., to the company’s board of directors. Dr. Pan will also serve as a member of the board’s audit committee and the nominating committee. Dr. Pan is currently serving as chief medical officer at Thrasys, Inc. He has over 20 years of broad healthcare industry experience in clinical medicine, managed care and health information technology.

“Wayne’s experience in building and leading teams in healthcare technology and managed care, brings great value to Semler and to our board of director as we build our sales and marketing efforts and develop new products,” said Doug Murphy-Chutorian, M.D., chief executive officer of Semler.

Since August 2012, Dr. Pan has been chief medical officer at Thrasys, Inc., a global healthcare technology company that provides a cloud-based platform upon which healthcare delivery systems and provider organizations can build high quality, person-centered accountable care communities. Prior to Thrasys Inc., Dr. Pan was concurrently the chief medical informatics officer for Health Access Solutions, a health care software development company, from 2010 to 2012 and chief medical officer of Pacific Partners Management Services, Inc., a management services organization managing medical groups in northern California with over 50,000 covered lives. Prior to that, Dr. Pan served as chief medical officer at Affinity Medical Solutions, LLC, a medical management services organization serving independent physicians association clients and managing commercial and Medicare Advantage members, from 2009 to 2010. Dr. Pan also held the position of chief medical officer from 2008 to 2009 for Alameda Alliance for Health, a local initiative health plan with Medicaid, Medicare Advantage and IHSS plans, and the position of advisory chief medical officer at a data analytics start-up focused on big data issues in healthcare in 2007 to 2008. Dr. Pan completed his undergraduate studies in Biology at Johns Hopkins University, his M.D. and Ph.D. degrees concurrently at Mt. Sinai School of Medicine, and he has an MBA from the Wharton School of the University of Pennsylvania.

Dr. Pan is being appointed to fill a vacancy created by the resignation from the company’s board of directors of Mr. Elliot A. Sainer.

About Semler Scientific, Inc.:

Semler Scientific, Inc. is an emerging medical risk-assessment company. Its mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services. Semler’s first patented and U.S. Food and Drug Administration, or FDA, cleared product, is FloChec®. FloChec® is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements. FloChec® received FDA 510(k) clearance in February 2010, Semler began Beta testing in the third quarter of 2010, and Semler began commercially leasing FloChec® in January 2011. Semler closed the initial public offering of its common stock on February 26, 2014 and its common stock is now listed on the NASDAQ Capital Market under the ticker symbol “SMLR.” Additional information about Semler can be found at www.semlerscientific.com.

CONTACT:

Susan A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
212 966 3650

Wednesday, May 14th, 2014 Uncategorized Comments Off

(CTHR) Announces Annual Meeting of Shareholders

Live Video Webcast on May 21, 2014 at 10:00 AM EDT

Charles & Colvard, Ltd. (NASDAQ Global Select Market:CTHR), the sole source of created moissanite and Forever Brilliant^®, The World’s Most Brilliant Gem^®, announces that its Annual Meeting of Shareholders, to be held Wednesday, May 21, 2014 at 10:00 am EDT, will be streamed live via video webcast.

The live video webcast can be accessed at http://www.charlesandcolvard.com/investors/webcast. Participants should go to the website 10 to 15 minutes prior to the scheduled video webcast in order to register and download any necessary software.

The recorded video webcast can be found at http://www.charlesandcolvard.com/investors/webcast and will be available approximately one hour after the conclusion of the live video webcast.

About Charles & Colvard, Ltd.

Charles & Colvard, Ltd., is the global sole source of moissanite, a unique, near-colorless created gem that is distinct from other gems and jewels based on its exceptional fire, brilliance, luster, durability, and rarity. Charles & Colvard Created Moissanite^® and Forever Brilliant^® are currently incorporated into fine jewelry sold through domestic and international retailers and other sales channels. Charles & Colvard, Ltd.’s common stock is listed on the NASDAQ Global Select Market under the symbol “CTHR.” For more information, please visit www.charlesandcolvard.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements expressing expectations regarding our future and projections relating to products, sales, revenues, and earnings are typical of such statements and are made under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations, and contentions and are not historical facts and typically are identified by use of terms such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “continue,” and similar words, although some forward-looking statements are expressed differently.

All forward-looking statements are subject to the risks and uncertainties inherent in predicting the future. You should be aware that although the forward-looking statements included herein represent management’s current judgment and expectations, our actual results may differ materially from those projected, stated, or implied in these forward-looking statements as a result of many factors including, but not limited to, our dependence on consumer acceptance and growth of sales of our products resulting from our strategic initiatives; dependence on a limited number of customers; the impact of the execution of our business plans on our liquidity; our ability to fulfill orders on a timely basis; the financial condition of our major customers; dependence on Cree, Inc. as the sole current supplier of the raw material; our current wholesale customers’ potential perception of us as a competitor in the finished jewelry business; intense competition in the worldwide jewelry industry; general economic and market conditions, including the current economic environment; risks of conducting business in foreign countries; the pricing of precious metals, which is beyond our control; the potential impact of seasonality on our business; our ability to protect our intellectual property; the risk of a failure of our information technology infrastructure to protect confidential information and prevent security breaches; possible adverse effects of governmental regulation and oversight, including regulations related to conflict minerals; and the failure to evaluate and integrate strategic opportunities, in addition to the other risks and uncertainties described in our filings with the Securities and Exchange Commission, or the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and subsequent reports filed with the SEC. Forward-looking statements speak only as of the date they are made. We undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur except as required by the federal securities laws, and you are urged to review and consider disclosures that we make in the reports that we file with the SEC that discuss other factors relevant to our business.

Wednesday, May 14th, 2014 Uncategorized Comments Off

(AGIO) Appoints Chris Bowden, M.D., as Chief Medical Officer

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced the appointment of Chris Bowden, M.D., to the newly created position of chief medical officer, where he will oversee global clinical development and regulatory initiatives for Agios. Dr. Bowden, who brings more than 17 years of experience in clinical drug development, including the approval of several cancer medicines, was previously vice president, product development oncology, franchise lead (Signaling Group) at Genentech, Inc., a member of the Roche Group.

“We are thrilled that Chris is bringing to Agios his strong industry and operational leadership at a time when our three oral, first-in-class product candidates are advancing in the clinic,” said David Schenkein, M.D., chief executive officer of Agios. “Chris has deep experience in oncology drug development, including the use and approval of companion diagnostics, which will prove valuable for our clinical development and registration strategies. His career-long focus on patient quality of care is an excellent fit with our vision and culture, which is dedicated to making a fundamental difference in patients’ lives.”

“I’m excited to join Agios at this time of important growth and evolution for the company,” said Dr. Bowden. “Agios is leading the investigation of precision medicine in the field of cellular metabolism, and has rapidly advanced several promising oral medicines to treat a range of serious diseases. Together with our experienced leadership team, I look forward to helping the company and our collaborator, Celgene, continue to accelerate the development of our pipeline and bring innovative new medicines to patients.”

During Dr. Bowden’s eight years at Genentech, he was responsible for the successful development of a number of novel oncology medicines. He led the teams responsible for the development and global registrations of several marketed cancer medicines, including Zelboraf® indicated for the treatment of BRAF V600E mutant-positive metastatic melanoma, Tarceva® indicated for the first line therapy of patients with non-small cell lung cancer whose tumors have an activating mutation of the Epidermal Growth Factor receptor (EGFR), and Erivedge® for patients with unresectable, locally advanced or metastatic basal cell carcinoma. From 2003 to 2006, Dr. Bowden was the executive director for EMEA (Europe, Middle East, Africa) regions for Bristol-Myers Squibb. In this role, he led medical affairs strategies for cancer, immunology and pain medicines. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development, Phases I-III, at Pharmacia Corporation and Janssen Pharmaceutica. Prior to his industry experience, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center where he participated in numerous industry and cooperative group trials. Dr. Bowden received his medical degree from Hahnemann University School of Medicine in Philadelphia followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology.

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and inborn errors of metabolism, or IEMs, which are rare genetic metabolic diseases, through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the expected benefits of Dr. Bowden’s employment and Agios’ strategic plans and focus. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios’ ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios’ ability to maintain key collaborations, such as its agreement with Celgene; and general economic and market conditions. These and other risks are described in greater detail under the caption “Risk Factors” included in Agios’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, and other filings that Agios may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Wednesday, May 14th, 2014 Uncategorized Comments Off

(CACH) Announces Participation in the B. Riley & Co. 15th Annual Investor Conference

Cache Inc., (NASDAQ:CACH), a specialty chain of women’s apparel stores, today announced that the Company will be participating in the B. Riley & Co. 15^th Annual Investor Conference held at Loews Santa Monica Beach Hotel in Santa Monica, on Wednesday, May 21, 2014 at 8:30 a.m. Pacific Time. Jay Margolis, Chairman and Chief Executive Officer, and Anthony DiPippa, Executive Vice President and Chief Financial Officer will host the presentation.

About Cache, Inc.

Cache is a nationwide, mall-based specialty retailer of apparel and accessories. Cache offers a boutique shopping experience for stylish and fashion-conscious women with a product line consisting of elegant evening wear, event and day dresses, casual sportswear and accessories, primarily sold under the Cache brand- everything to meet the events and lifestyle needs in a woman’s life. The Company currently operates 239 stores, primarily situated in central locations in high traffic, upscale malls in 41 states, the Virgin Islands and Puerto Rico.

Wednesday, May 14th, 2014 Uncategorized Comments Off

(CLDX) Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets

Whitefish, MT / May 14, 2014 / Pharmaceutical companies big and small are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are receiving the praise of analysts as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465. Shares of Celldex Therapeutics (NASDAQ: CLDX) are chugging ahead by 25 percent on Wednesday after striking a deal with Bristol-Myers Squibb (NYSE: BMY) to collaborate on the clinical development of BMY’s PD-1 investigational drug nivolumab in combination with Celldex’s CD27-targeting drug candidate varlilumab.

That’s just the tip of the cancer iceberg that has the biotech sector buzzing recently. Also in the immune suppression space is AstraZeneca’s (NYSE: AZN) MedImmune unit partnering with Incyte (NASDAQ: INCY) to couple MedImmune’s MEDI4736 with Incyte’s INCB24360 in another PD-L1 program. This pact was in the making against the backdrop of MedImmune working with Pfizer (NYSE: PFE) on an anti-CTLA-4 combination therapy as Pfizer wrangles with Parliament to try and acquire AstraZeneca for more than $100 billion.

Believe it or not, all of these new therapeutic targets have one thing in common: exosomes. Exosomes were historically thought of as simply cellular debris, but a growing body of evidence has proven the tiny microvesicles to be integral in cellular communication, including carrying and spreading diseased cells throughout the circulatory system. The capturing of exosomes has great implications in advancing treatments for many diseases, including cancer. On that point, Aethlon Medical (OTCQB: AEMD) has a platform technology to do just that. The company’s flagship product, the Hemopurifier(R), is an extracorporeal filtration device utilizing a carbohydrate-binding protein to clear the bloodstream of exosomes (or other disease targets, as shown through a clinical trial demonstrating its potential for treating HIV or hepatitis C).

Aethlon Chairman and CEO Jim Joyce released a note to shareholders today effectively detailing how the Hemopurifier could serve as a valuable technology in the next generation of cancer therapies, certainly not confined to only the immuno-oncology aspect. The Aethlon chief notes a litany of companies and their oncology targets, such as CD20, HER2, EGFR and more, to demonstrate the broad spectrum of cellular pathways that the Hemopurifier could potentially address either independently or in conjunction with existing drugs and those in development.

Biotechnology investors are encouraged to read the complete CEO note here: http://aethlonmedical.investorroom.com/2014-05-14-Aethlon-Medical-AEMD-CEO-Note-Cancer-Treatment-Discovery-Exosomes-Transport-Pharmaceutical-Industry-Targets

Click here to sign up for free email updates on Aethlon Medical developments: http://www.emerginggrowthcorp.com/emailassets/aemd/aemd_landing.php

Disclosure

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx

Wednesday, May 14th, 2014 Uncategorized Comments Off

(PTX) Signs Agreement to Acquire TREXIMET® Tablets for Migraine From GSK

Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that it has signed an agreement with GlaxoSmithKline (NYSE: GSK) to acquire the U.S rights to Treximet^® (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Pernix’s team of approximately 90 specialty sales professionals will support the sales and marketing of Treximet^®.

Doug Drysdale, Chairman, President and CEO of Pernix noted, “The acquisition of Treximet^® further accelerates the transformation of Pernix into a specialty pharmaceutical company and expands our portfolio of CNS brands, Silenor^® and Khedezla^TM. With the strong presence Pernix is establishing in the adjacent psychiatric market, this acquisition provides Pernix an opportunity to expand the company’s reach and penetration into the very important neurology space.”

Transaction Benefits

Adds immediate revenues and earnings, FY2013 Treximet^® net sales $78.7 million
Leverages Pernix’s existing sales presence and experience across psychiatry and neurology customers
Expected to nearly double Pernix revenues and provide EBITDA margins in excess of 30% on a FY2014 pro forma basis
Pernix estimates pro forma FY2015 total company revenues will exceed $230 million with an EBITDA margin of over 40%

Transaction Details

Pernix will make an upfront payment to GSK of $250 million for the U.S rights to Treximet^®
GSK will assign to Pernix the Product Development and Commercialization Agreement (“PDC Agreement”) between GSK and POZEN, Inc. (NASDAQ: POZN)
POZEN and Pernix will amend the PDC Agreement to facilitate further development of Treximet^®
The Company will purchase existing inventory from GSK and GSK will continue to manufacture Treximet^® in the near future under a long-term Supply Agreement with Pernix
The Company expects the transaction to close and to transfer Treximet^®no later than August 1, 2014 following Hart Scott Rodino approval and closing of financing by Pernix
The Company will continue to make royalty payments on net sales of the product
The transaction will be financed through a combination of cash, debt and equity-linked or other securities

Operational Plan

Pernix expects to begin sales of Treximet^® immediately following the closing of the transaction with its approximately 90 sales professionals to specific targets in the Neurology, Psychiatry and the Primary Care audiences.
Pernix is ready to take advantage of minimal branded competition in a promotionally sensitive market with a staged re-launch of Treximet^® with increased promotion, including a revised campaign for Healthcare professionals and consumers, as well as specific tactics addressing managed care and pharmacy programs.
Treximet^® is currently the lowest priced branded migraine treatment available, yet provides superior pain relief compared to placebo and to both of the single mechanism of action components.
Pernix also plans to seek an extension of the exclusivity of Treximet^® with the first ever pediatric indication (age 12 to 17) for any sumatriptan treatment, expected to file by the end of 2014, as well as additional life-cycle opportunities that are currently being explored. Pernix will pay GSK additional consideration of $17 million upon receipt of updated FDA Written Request for pediatric exclusivity.

Under the amended PDC Agreement, Pernix will complete the filing for a pediatric indication for Treximet^® and undertake certain new activities to extend the product’s life. In addition, Pernix will release restrictions on POZEN’s right to develop and commercialize additional dosage forms of sumatriptan/naproxen combinations outside of the United States.

In connection with the assignment of the PDC Agreement, Pernix shall make a payment of $3 million to CPPIB Credit Investments Inc. and has also granted POZEN a warrant to purchase 500,000 shares of Pernix common stock at an exercise price equal to the closing market price on May 13, 2014. The warrants will be exercisable from the closing date of the transaction until February 2018.

The amended PDC Agreement provides for royalties of 18% of net sales with quarterly minimum royalty amounts of $4 million for the calendar quarters commencing on January 1, 2015 and ending on March 31, 2018.

Treximet^® was first approved by the U.S. Food and Drug Administration (FDA) in April 2008 for the acute treatment of migraine attacks, with or without aura, in adults. The product is formulated with POZEN’s patented technology of combining a triptan with a non-steroidal anti-inflammatory drug (NSAID) and GlaxoSmithKline’s (GSK) RT Technology™. Treximet^® has been shown to provide superior sustained pain relief compared to placebo and to both of the single mechanism of action components.

In clinical trials, Treximet^® provided a significantly greater percentage of patients migraine pain relief at two hours compared to sumatriptan 85mg or naproxen sodium 500 mg alone. In addition, Treximet^® provided more patients sustained migraine pain relief from two to 24 hours compared to the individual components.

Important safety information about Treximet^®

Prescription Treximet^® is indicated for the acute treatment of migraine attacks, with or without aura, in adults. Carefully consider the potential benefits and risks of Treximet^®and other treatment options when deciding to use Treximet^®. Treximet^®is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Treximet^®have not been established for cluster headache. Treximet^® should only be used where a clear diagnosis of migraine headache has been established. Treximet^® may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Treximet^® contains a non-steroidal anti-inflammatory drug (NSAID). NSAID-containing products cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. Treximet^® is contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes and in patients with other significant underlying cardiovascular diseases. Treximet^® should not be given to patients in whom unrecognized coronary artery disease is predicted by the presence of risk factors without a prior cardiovascular evaluation. Treximet^® should not be given to patients with uncontrolled hypertension because the components have been shown to increase blood pressure. Concurrent administration of MAO-A inhibitors or use of Treximet^® within two weeks of discontinuation of MAO-A inhibitor therapy is contraindicated. Treximet^® and any ergotamine-containing or ergot-type medication (like dihydroergotamine and mthysergide) should not be used within 24 hours of each other. Since Treximet^® contains sumatriptan, it should not be administered with another 5-HT1 agonist.

Treximet^® is contraindicated in patients with hepatic impairment. Treximet^® is contraindicated in patients who have had allergic reactions to products containing naproxen. It is also contraindicated in patients in whom aspirin or other NSAIDs/analgesic drugs induce the syndrome of asthma, rhinitis, and nasal polyps. Both types of reactions have the potential of being fatal. Treximet^® is contraindicated in patients with hypersensitivity to sumatriptan, naproxen, or any other component of the product. Cerebrovascular events have been reported in patients treated with sumatriptan. In a number of cases, it appears possible that the cerebrovascular events were primary. It is important to advise patients not to administer Treximet^® if a headache being experienced is atypical. The development of a potentially life-threatening serotonin syndrome may occur with triptans, including treatment with Treximet^®, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs). NSAID-containing products, including Treximet^®, should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding. Treximet should not be used in late pregnancy because NSAID-containing products have been shown to cause premature closure of the ductus arteriosus. Treximet^® should not be used during early pregnancy unless the potential benefit justifies the potential risk to the fetus.

Conference Call Information

Management will host a conference call today at 10:00 a.m. EDT during which Douglas Drysdale, President and Chief Executive Officer will review the Company’s acquisition of TREXIMET^®. The slides of Mr. Drysdale’s presentation will be available on our website at www.pernixtx.com at 8:30 a.m. EDT this morning. To participate in the live conference call, please dial (877) 312-8783 (domestic) or (408) 940-3874 (international), and provide conference ID code 47132477. A live webcast of the call will also be available on the investor relations section of the Company’s website, www.pernixtx.com. Please allow extra time prior to the webcast to register and download and install any necessary audio software.

A replay of the call will be available through May 21, 2014. To access the replay, please dial (855) 859-2056 (domestic) and (404) 537-3406 (international), and provide conference ID code 47132477. An online archive of the webcast will be available on the Company’s website for 30 days following the call.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: SILENOR^®, a non-narcotic product for the treatment of insomnia, and KHEDEZLA^™, as well as CEDAX^®, an antibiotic for middle ear infections and a number of treatments for cough and cold conditions including ZUTRIPRO^®, REZIRA^® and VITUZ^®. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Additional information about Pernix is available on the Company’s website located at www.pernixtx.com.

About Glaxo SmithKline (LSE & NYSE: GSK)

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For detailed company information, see GlaxoSmithKline’s website: www.gsk.com.

About POZEN

POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN is currently seeking strategic partners to help maximize the opportunities for its portfolio assets.

The Company’s common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.POZEN.com.

Cautionary Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “target” or similar expressions are forward-looking statements. Because these statements reflect the Company’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect the Company’s future financial results and could cause actual results to differ materially from those expressed in forward-looking statements contained in the Company’s Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Wednesday, May 14th, 2014 Uncategorized Comments Off

(PLUG) to Present at Wedbush Annual Conference

LATHAM, N.Y., May 13, 2014 — Plug Power Inc. (Nasdaq:PLUG), a leader in providing clean, reliable energy solutions announces that Chief Operating Officer, Keith Schmid, will present the Company’s strategy to investors today, May 13, 2014 at the Wedbush 2014 Transformational Technologies Management Access Conference. Mr. Schmid will present at 8:35 am ET.

A live webcast of Mr. Schmid’s presentation can be accessed directly at http://wsw.com/webcast/wedbush27/plug/ , or by visiting the Plug Power Web site (www.plugpower.com) and selecting the conference link on the home page. The webcast will be archived for 90 days following the live presentation.

About Plug Power Inc.

The architects of modern fuel cell technology, Plug Power is revolutionizing the industry with cost-effective power solutions that increase productivity, lower operating costs and reduce carbon footprints. Long-standing relationships with industry leaders, including Walmart, Sysco, Procter & Gamble, and Mercedes Benz, forged the path for Plug Power’s innovative GenKey hydrogen and fuel cell system solutions. With more than 4,500 GenDrive units deployed to material handling customers, accumulating over 20 million hours of runtime, Plug Power manufactures tomorrow’s incumbent power solutions today. Additional information about Plug Power is available at www.plugpower.com.

Plug Power Inc. Safe Harbor Statement

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Plug Power Inc. (“PLUG”), including but not limited to statements about PLUG’s forecast of financial performance, products and services, business model, strategy and growth opportunities, and competitive position. You are cautioned that such statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, such performance or results will have been achieved. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. In particular, the risks and uncertainties include, among other things, the risk that we continue to incur losses and might never achieve or maintain profitability; the risk that we will need to raise additional capital to fund our operations and such capital may not be available to us; our lack of extensive experience in manufacturing and marketing products may impact our ability to manufacture and market products on a profitable and large-scale commercial basis; the risk that unit orders will not ship, be installed and/or converted to revenue, in whole or in part; the risk that pending orders may not convert to purchase orders, in whole or in part; the risk that a loss of one or more of our major customers could result in a material adverse effect on our financial condition; the risk that a sale of a significant number of shares of stock could depress the market price of our common stock; the risk that negative publicity related to our business or stock could result in a negative impact on our stock value and profitability; the risk of potential losses related to any product liability claims and contract disputes; the risk of loss related to an inability to maintain an effective system of internal controls or key personnel; risks related to use of flammable fuels in our products; the cost and timing of developing, marketing and selling our products and our ability to raise the necessary capital to fund such costs; the ability to achieve the forecasted gross margin on the sale of our products; the risk that our actual net cash used for operating expenses may exceed the projected net cash for operating expenses; the cost and availability of fuel and fueling infrastructures for our products; market acceptance of our products, including GenDrive systems; the volatility of our stock price; our ability to establish and maintain relationships with third parties with respect to product development, manufacturing, distribution and servicing and the supply of key product components; the cost and availability of components and parts for our products; our ability to develop commercially viable products; our ability to reduce product and manufacturing costs; our ability to successfully expand our product lines; our ability to successfully expand internationally; our ability to improve system reliability for our GenDrive systems; competitive factors, such as price competition and competition from other traditional and alternative energy companies; our ability to protect our intellectual property; the cost of complying with current and future federal, state and international governmental regulations; risks associated with potential future acquisitions; and other risks and uncertainties referenced in our public filings with the Securities and Exchange Commission. For additional disclosure regarding these and other risks faced by PLUG, see disclosures contained in PLUG’s public filings with the Securities and Exchange Commission (the “SEC”) including, the “Risk Factors” section of PLUG’s Annual Report on Form 10-K for the year ended December 31, 2013. You should consider these factors in evaluating the forward-looking statements included in this presentation and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and PLUG undertakes no obligation to update such statements as a result of new information.

CONTACT: Plug Power Contact:
         Teal Vivacqua
         518.738.0269
         investor_relations@plugpower.com

Tuesday, May 13th, 2014 Uncategorized Comments Off

(FCEL) Announces Strengthening of Strategic Relationship With POSCO Energy

Collaboration on development of global customer opportunities
Integrated global supply chain agreement enhances reliability of supply and supports product cost reductions
FuelCell Energy sells 5.6 megawatts of fuel cell modules to POSCO Energy to meet growing Asian demand

DANBURY, Conn., May 13, 2014 — FuelCell Energy, Inc. (Nasdaq:FCEL), a global leader in the design, manufacture, operation and service of ultra-clean, efficient and reliable fuel cell power plants, announced further steps to accommodate the increasing global demand for megawatt-class stationary fuel cell power plants, ensuring preeminent customer support around the world as well as enhanced execution of product cost reductions. FuelCell Energy and POSCO Energy are collaborating to support multi-national customers expressing interest in fuel cell projects in the other partner’s territory, are further synchronizing the integrated global supply chain, and executing the sale of four fuel cell modules, totaling 5.6 megawatts to meet rising demand in Asia.

“Even closer collaboration between POSCO Energy and FuelCell Energy ensures that our respective customers receive the enhanced value and security for their investment as we reduce costs and further enhance the overall competitiveness of clean distributed fuel cell power generation,” said Jung-Gon Kim, Senior Vice President of POSCO Energy.

Increasing interest in stationary fuel cell applications in different geographic regions from companies with global operations has led to the broadening of activities between FuelCell Energy and POSCO Energy. Enhanced collaboration accommodates North American, European or other non-Asian customers of FuelCell Energy that are interested in a fuel cell installation in Asia as well as Asian customers of POSCO Energy that desire a fuel cell installation outside of Asia. With growing global adoption of Direct FuelCell^® power plants, trends to larger-sized fuel cell parks, and cross-territorial interest from multi-national customers, FuelCell Energy and POSCO Energy can support global customers in each other’s local market to ensure consistency of communication, quality and execution.

The construction of the POSCO Energy cell manufacturing facility is on schedule with production expected in mid-2015. Once operational, this facility will double the global manufacturing capacity of FuelCell Energy’s proprietary power plants.

The integrated global supply chain agreement reaffirms the global supply chain alignment, which is critical for expected product cost reductions. Decreasing product costs supports further market adoption as well as margin expansion. The combined purchasing volume of both organizations results in both partners benefitting from purchases by each other through lower product costs. By leveraging the existing supply advantages of both companies, including POSCO’s steel manufacturing capabilities and mining operations, FuelCell Energy will realize enhanced security of supply and increasing production volumes in any one region benefits both partners with lower product costs globally.

“The relationship we have with POSCO Energy is a differentiator in the fuel cell industry as we work together to continue to grow the market while further driving down product costs and improving project financial returns,” said Chip Bottone, President and CEO of FuelCell Energy. “As a leading global steel manufacturer, POSCO’s investment in market development, manufacturing capacity, and partial ownership in FuelCell Energy are additional points of validation for our affordable, ultra-clean, and secure power generation solutions while manufacturing in more than one location mitigates risk for the customer base.”

During the second quarter of 2014, FuelCell Energy sold four fuel cell modules totaling 5.6 megawatts to POSCO Energy. These modules are in addition to the monthly fuel cell kit shipments under an existing 122 megawatt order. This second quarter 2014 5.6 megawatt module purchase, as well as the previously announced first quarter 2014 2.8 megawatt module purchase, will both support new installations that POSCO is completing this calendar year for its customers in Korea.

“The timing of these module orders supports specific projects in Asia as the ability to construct multi-megawatt fuel cell parks in short time frames of about a year is a differentiator in the power generation market and the short construction period helps to minimize capital costs,” continued Mr. Bottone. “The ability to rapidly construct a fuel cell park of ten to sixty megawatts enables utilities to add clean baseload power where they need it within their service territory while avoiding the cost and permitting challenges of transmission lines.”

POSCO Energy is a wholly owned subsidiary of POSCO, a leading global steel producer headquartered in Pohang, South Korea. POSCO Energy is an independent power producer with power generation assets in South Korea that provide power to POSCO and to the electric grid. POSCO Energy owns more than 3,000 megawatts of power generation including generation assets in Southeast Asian countries including Indonesia and Vietnam, as well as a solar park in Nevada, USA. POSCO Energy 2013 sales totaled $2.8 billion supported by total capital of $1.5 billion. The parent, POSCO, is publicly traded on the Korean Stock Exchange under the symbol 005490 and on the New York Stock Exchange under the symbol PKX.

Multi-megawatt fuel cell parks solve power generation challenges for utilities as the combination of near-zero pollutants, modest land-use needs, and the quiet operating nature of fuel cell power plants facilitates their siting in urban locations. Fuel cell parks offer a multitude of advantages for utilities and neighboring communities, including:

Environmentally friendly power generation with virtually zero nitrogen oxide (NO_x) that causes smog, sulfur dioxide (SO_x) that contributes to acid rain, or particulate matter (PM¹⁰) that aggravates asthma, and the power is delivered with a low carbon footprint
Distributed power generation places power near where it is used, enhancing the resiliency of the grid
Highly efficient power generation process that is economical
Continuous renewable power around the clock that is not reliant on weather or time of day

DFC^®power plants utilize carbonate fuel cell technology, which is well suited for megawatt-class applications due to the scalability and favorable cost profile. Another advantage is that carbonate cells operate efficiently without the need for noble metal catalysts, such as platinum, which are required by some other types of fuel cell technology.

About FuelCell Energy

Direct FuelCell® power plants are generating ultra-clean, efficient and reliable power at more than 50 locations worldwide. With more than 300 megawatts of power generation capacity installed or in backlog, FuelCell Energy is a global leader in providing ultra-clean baseload distributed generation to utilities, industrial operations, universities, municipal water treatment facilities, government installations and other customers around the world. The Company’s power plants have generated more than two billion kilowatt hours of ultra-clean power using a variety of fuels including renewable biogas from wastewater treatment and food processing, as well as clean natural gas. For more information, please visit www.fuelcellenergy.com

See us on YouTube

Direct FuelCell, DFC, DFC/T, DFC-H2 and FuelCell Energy, Inc. are all registered trademarks of FuelCell Energy, Inc. DFC-ERG is a registered trademark jointly owned by Enbridge, Inc. and FuelCell Energy, Inc.

CONTACT: FuelCell Energy, Inc.
         Kurt Goddard, Vice President Investor Relations
         203-830-7494
         ir@fce.com

Tuesday, May 13th, 2014 Uncategorized Comments Off

(UBNT) Introduces UniFi Video Platform and Camera Line

Unified Control and Management of New IP Surveillance Cameras Now Part of Ubiquiti’s UniFi Family of Products

SAN JOSE, Calif., May 13, 2014 — Ubiquiti Networks, Inc. (Nasdaq:UBNT), a next-generation communications technology company, today announced that it has launched UniFi Video, a new line of video surveillance camera control software and a new generation of cameras – the UVC, UVC-Dome, and UVC-Pro models – to join the UniFi family of products. The new camera control software will be backwards compatible with all Ubiquiti airVision cameras, significantly improving the UI and functionality of the existing airVision platform.

The new offerings will include the addition of numerous enterprise-grade features, including:

Advanced recording. All units support 720P recording, IR illumination, and a high-quality sensor. UVC Pro cameras also support 1080p recording, extreme weather protection and 3x zoom.
Live view and HD feed capability. Live view allows you to view multiple live camera feeds in highly customizable arrangements, and live feeds and recordings are high resolution supporting up to 1080p/30FPS.
Simple configuration and software/firmware upgrades. Deep integration with our cameras allow you to configure and upgrade any number of cameras easily and quickly all within the UniFi Video user interface.
Comprehensive controller dashboard. Interactive statistical graphs aid in quickly finding and viewing recordings, and zone analytics allow you to precisely define areas of interest for motion recording and notification, including a heat map for motion-triggered video recordings.
Access controls. User and user group functionality gives access for multiple users with different permissions.
Easy remote management. Email alerts allow near instant notification of when motion occurs and a mobile web UI allows the viewing of recordings and status of security while on the road or away from location.
Broadcast capability to third-party software. The controller can broadcast managed video streams to third-party software to manage and review video feeds.

“We have invested significant R&D in fine tuning our video surveillance technology and developing UniFi Video,” said Ben Moore, vice president of business development at Ubiquiti Networks. “The launch of UniFi Video allows us to extend the capability of UniFi, adding more value to our Enterprise Technology offerings.”

For more information on UniFi Video, visit http://uv.ubnt.com/.

About Ubiquiti Networks

Ubiquiti Networks (Nasdaq:UBNT) is closing the digital divide by building network communication platforms for everyone and everywhere. With over 20 million devices deployed in over 180 countries, Ubiquiti is transforming under-networked businesses and communities. Our leading edge platforms, airMAX®, UniFi®, airFiber®, airVision®, mFi® and EdgeMAX® combine innovative technology, disruptive price performance and the support of a global user community to eliminate barriers to connectivity. For more information, join our community at http://www.ubnt.com.

Ubiquiti, the Ubiquiti logo, Ubiquiti Networks, airMAX, NanoBeam, airFiber, airVision, UniFi, mFi, EdgeMAX, EdgeRouter, InnerFeed, xRT, and World Network are registered trademarks or trademarks of Ubiquiti Networks, Inc. and/or its affiliates in the United States and other countries. All other trademarks mentioned in this document are the property of their respective owners.

The Ubiquiti Networks, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=24865

Safe Harbor for Forward Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements other than statements of historical fact including words such as “look,” “will,” “anticipate,” “believe,” “estimate,” “project,” “expect,” “consider,” “schedule” and “plan” and statements in the future tense are forward looking statements. The statements in this press release that could be deemed forward-looking statements include statements regarding release of new products and expected performance, price-performance disruptiveness, growth prospects, product applications, expected performance and potential benefits, market positioning, short and long-term opportunities, and any statements or assumptions underlying any of the foregoing. You should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date made. Ubiquiti Networks undertakes no obligation to update information contained in this press release. You should review our SEC filings carefully, particularly the discussions under the heading “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended June 30, 2013 and other filings filed with the U.S. Securities and Exchange Commission that identify risks that could cause actual results to differ from those made in such forward-looking statements. Copies may be obtained by contacting the Ubiquiti Networks Investor Relations Department by email at IR@ubnt.com or by visiting the Investor Relations section of the Ubiquiti Networks website, http://ir.ubnt.com.

CONTACT: Media Contact:
         Ben Moore
         Vice President, Business Development
         Ubiquiti Networks, Inc.
         press@ubnt.com

Tuesday, May 13th, 2014 Uncategorized Comments Off

(SEED) Announces Receipt of Acquisition Proposal

BEIJING, May 13, 2014 — Origin Agritech Limited (NASDAQ GS: SEED) (“Origin“, or the “Company“), a technology-focused supplier of crop seeds in China, today announced that its Board of Directors has received a preliminary non-binding proposal letter, dated May 12, 2014, from Hunan Xindaxin Company Limited (“Xindaxin“), pursuant to which Xindaxin proposes to acquire the Company (the “Transaction“) for US$2.50 in cash per ordinary share of the Company. Xindaxin is the controlling shareholder of Yuan Longping Hi-Tech Agriculture Co., Ltd., a China-based company listed on the Shenzhen Stock Exchange primarily engaged in the research, production and sale of agricultural products. A copy of the proposal letter is attached hereto as Appendix 1.

The Company’s Board of Directors is reviewing and evaluating Xindaxin’s proposal and cautions the Company’s shareholders and others considering trading in the Company’s securities that the Board of Directors has not yet made any decisions with respect to the proposed Transaction, or the Company’s response to the proposed Transaction. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required under applicable law.

About Origin

Founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, Origin Agritech Limited (NASDAQ GS: SEED) is China’s leading agricultural biotechnology company, specializing in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services. Leading the development of crop seed biotechnologies, Origin’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. Origin operates production centers, processing centers and breeding stations nationwide with sales centers located in key crop-planting regions. Product lines are vertically integrated for corn, rice and canola seeds. For further information, please log on to the Company’s website at: www.originseed.com.cn.

Forward Looking Statement

This release contains forward-looking statements. All forward-looking statements included in this release are based on information available to us on the date hereof. These statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results to differ materially from those implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “targets,” “goals,” “projects,” “continue,” or variations of such words, similar expressions, or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Neither we nor any other person can assume responsibility for the accuracy and completeness of forward-looking statements. Important factors that may cause actual results to differ from expectations include, but are not limited to, those risk factors discussed in Origin’s filings with the SEC including its annual report on Form 20-F filed on January 23, 2014. We undertake no obligation to revise or update publicly any forward-looking statements for any reasons.

Appendix I: http://photos.prnasia.com/prnh/20140513/0861403174

CONTACT:

Origin Agritech Limited
Dr. James Chen
Chief Financial Officer
james.chen@originseed.com.cn

Kay Liu
Investor Relations
ke.liu@originseed.com.cn
+86-138-1193-7764

Tuesday, May 13th, 2014 Uncategorized Comments Off

(TWOU) Executives Named Finalists for a Range of Business and Technology Awards

2U CTO and CFO nominated in both Tech Council of Maryland and Northern Virginia Technology Council Awards

LANDOVER, Md., May 13, 2014 — 2U, Inc. (NASDAQ: TWOU), a leading provider of cloud-based software-as-a-service solutions that enables leading nonprofit colleges and universities to deliver high-quality education, announced today that the company, its Chief Technology Officer (CTO) and its Chief Financial Officer (CFO) have all been nominated for a host of industry awards.

2U has been nominated for 2014 Technology Firm of the Year by Maryland’s largest technology trade association, the Tech Council of Maryland (TCM). The TCM also nominated 2U’s James Kenigsberg as the 2014 CTO of the Year for his work as a leader and technology innovator for the company. Winners will be announced at the TCM 26^th annual celebration on May 15.

2U’s CFO, Cathy Graham, has also been named a finalist for the Northern Virginia Technology Council’s 2014 Greater Washington Technology CFO Awards – a recognition of chief financial officers and financiers for outstanding achievement and excellence in promoting the D.C. area’s tech community.

“Both James and Cathy show incredible leadership within our company, and bring tremendous drive and passion to help 2U fulfill its mission,” said Chip Paucek, co-founder and CEO of 2U. “To be acknowledged by these two notable technology councils is an honor, and wouldn’t be possible without the hard work of each 2U contributor who believes strongly in the vision of harnessing technology to further education. We congratulate all fellow nominees – some of the top tech organizations in the D.C. region.”

These award nominations follow 2U’s recent recognitions, including winning the Return on Education Innovation Award at the prestigious ASU+GSV Education Innovation Summit. 2U co-founder and CEO, Chip Paucek was also named one of the five Highest Ranked CEOs in the U.S. among small- to medium-sized companies and Top 20 Best Medium Sized Companies to Work for, both in 2014 by Glassdoor. Glassdoor is an online career and workplace community. In support of Paucek’s Glassdoor ranking, 2U employees created a two-minute video, explaining why they wanted to work at 2U and what it meant to work for a CEO like Paucek. The video can be found here.

2U is currently hiring in Landover, MD (near the Washington, DC area); New York City, NY; Los Angeles, CA and other locations. The company offers a high-energy work start-up environment that’s both challenging and fun. Please visit the company’s career page for more information: http://2u.com/about/careers or follow 2U on Twitter at @2Uinc or on Facebook at Facebook.com/2u.

About 2U, Inc. (NASDAQ: TWOU)
Founded in 2008 by a team of education and technology veterans, 2U enables leading colleges and universities to deliver their high-quality education to qualified students anywhere. Our cloud-based software-as-a-service platform provides schools with the comprehensive operating infrastructure they need to attract, enroll, educate, support and graduate their students. Our mission is to enable the education our clients provide to reach its highest potential so students can reach theirs. To learn more, go to 2U.com. Be sure to follow us on LinkedIn (http://www.linkedin.com/company/2u), Twitter (http://twitter.com/2Uinc) and Facebook (http://www.facebook.com/2u).

Media Contact: Loretta Jergensen
ljergensen@2u.com; 301-892-4408

Tuesday, May 13th, 2014 Uncategorized Comments Off

(TWOU) Executives Named Finalists for a Range of Business and Technology Awards

2U CTO and CFO nominated in both Tech Council of Maryland and Northern Virginia Technology Council Awards

Media Contact: Loretta Jergensen
ljergensen@2u.com; 301-892-4408

Tuesday, May 13th, 2014 Uncategorized Comments Off

(ICLD) Announces Conference Call to Discuss First Quarter Financial Results

SHREWSBURY, N.J., May 13, 2014 — In a release issued under the same headline earlier today by InterCloud Systems Inc. (Nasdaq:ICLD), please note that in the first paragraph of the release, the conference call is to discuss financial results for the first quarter ended March 31, 2014, not the third quarter ended September 30, 2013 as previously stated. The corrected release follows:

InterCloud Systems Inc. (Nasdaq:ICLD) (“InterCloud” or the “Company”), a single source provider of IT solutions through cloud platforms and professional services, will hold a conference call to discuss its financial results for the first quarter ended March 31, 2014. CEO Mark Munro and CFO Daniel Sullivan will participate in the call, which is scheduled for Friday, May 16 at 10:00 a.m. Eastern time (7:00 a.m. Pacific).

To participate in the call, please dial (877) 941-4774, or (480) 629-9760 for international calls, approximately 10 minutes prior to the scheduled start time. Interested parties can also listen via a live Internet webcast, which can be found via the Company’s website at www.intercloudsys.com, or alternately at http://public.viavid.com/confirmation/confirmwebcast.php?id=o5aropeb.

A replay of the call will be available for two weeks from 1:00 p.m. ET on May 16, 2014, until 11:59 p.m. ET on May 30, 2014. The number for the replay is (877) 870-5176, or (858) 384-5517 for international calls; the passcode for the replay is 4683910.

About InterCloud Incorporated

InterCloud Systems, Inc. is a single-source provider of end-to-end information technology (IT) and next-generation network solutions to the telecommunications service provider (carrier) and corporate enterprise markets through cloud platforms and professional services. InterCloud offers cloud and managed services, professional consulting and staffing services, and voice, data and optical solutions to assist its customers in meeting their changing technology demands. Its engineering, design, installation and maintenance services support the build-out and operation of some of the most advanced enterprise, fiber optic, Ethernet and wireless networks. Additional information regarding InterCloud may be found on the Company’s website at www.intercloudsys.com.

Forward-looking statements:

The above release contains forward-looking statements. The statements contained in this document that are not statements of historical fact, including but not limited to, statements identified by the use of terms such as “anticipate,” “appear,” “believe,” “could,” “estimate,” “expect,” “hope,” “indicate,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would,” and other variations or negative expressions of these terms, including statements related to expected market trends and the Company’s performance, are all “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of external factors, uncertainties, business risks, and other risks identified in filings made by the company with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based except as required by applicable law and regulations.

CONTACT: Investor Relations
         Mike Bowdoin
         RedChip Companies, Inc.
         Tel: +1-800-733-2447, ext. 110
         mike@redchip.com
         http://www.redchip.com

Tuesday, May 13th, 2014 Uncategorized Comments Off

(FRBK) Opens New Store in Voorhees, N.J.

Republic First Bancorp, Inc. (NASDAQ: FRBK), the holding company for Republic Bank, has opened a second Southern New Jersey retail store at 101 Laurel Oak Road in Voorhees. The new Voorhees location is an important next step in Republic Bank’s ‘The Power of Red is Back’ expansion plan as it continues Republic’s strong tradition of offering exceptional banking convenience and fantastic Customer-centric service.

Touting a design similar to its recently opened Cherry Hill location, the Voorhees store will feature Republic Bank’s unique all-glass cube, which aims to welcome Customers and present an inviting atmosphere in which to fulfill their banking needs.

With rapid growth in the recent months – much of it driven from “The Power of Red is Back” plan – Republic continues to expand its footprint in Southern New Jersey while enhancing its presence in the Metro Philadelphia region. In the coming months, Republic Bank will announce plans for stores in Marlton, Moorestown, Mount Holly, Medford, Glassboro, Washington Township and a second store in Cherry Hill.

“We are excited to serve our Customers in Voorhees at this beautiful new location, which enables them to fulfill their many banking needs in one stop,” said Harry Madonna, Chairman and Chief Executive Officer of Republic Bank. “Our recent store openings in Media, PA and Cherry Hill, NJ have reconnected us with many old friends, while providing us the opportunity to develop new community relationships. Our current and prospective Customers know the convenience and customer service we offer is unparalleled and our new Voorhees location continues our mission of exceeding our Customers’ expectations.”

As one of the largest Philadelphia-based retail banking institutions, Republic Bank now has 14 locations including stores in Abington, Ardmore, Bala Cynwyd, Plymouth Meeting, Media and Philadelphia, Pennsylvania and Cherry Hill, Haddonfield and Voorhees, New Jersey. Through extended hours seven days of the week, Republic Bank offers numerous Customer-centric benefits including absolutely free checking and coin counting and more than 55,000 surcharge-free ATMs worldwide.

Republic Bank’s next store location will open at 16^th and Market Streets in Center City Philadelphia in June 2014.

For more information about Republic Bank visit www.myrepublicbank.com.

About Republic Bank

Republic Bank is the operating name for Republic First Bank. Republic First Bank is a full-service, state-chartered commercial bank, whose deposits are insured up to the applicable limits by the Federal Deposit Insurance Corporation (FDIC). The Bank provides diversified financial products through its fourteen offices located in Abington, Ardmore, Bala Cynwyd, Plymouth Meeting, Media and Philadelphia, Pennsylvania and Cherry Hill, Voorhees and Haddonfield, New Jersey.

Forward-Looking Statements

Republic First Bancorp, Inc. (“the Company”) may from time to time make written or oral “forward-looking statements”, including statements contained in this release and in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements include statements with respect to the Company’s beliefs, plans, objectives, goals, expectations, anticipations, estimates, and intentions that are subject to significant risks and uncertainties and are subject to change based on various factors, many of which are beyond the Company’s control. These factors include competition, timing, credit risks of lending activities, changes in general economic conditions, price pressures on loan and deposit products, and other factors detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The words “may”, “could”, “should”, “would”, “believe”, “anticipate”, “estimate”, “expect”, “intend”, “plan”, and similar expressions are intended to identify forward-looking statements. All such statements are made in good faith by the Company pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by or on behalf of the Company, except as may be required by applicable law or regulations.

Monday, May 12th, 2014 Uncategorized Comments Off

(SYPR) to Demonstrate Cyber Security Lab at Tech-Ed North America

Sypris Electronics, LLC, a subsidiary of Sypris Solutions, Inc. (Nasdaq/NM: SYPR), will be demonstrating its Cyber Security Lab at TechEd North America on May 12-14. TechEd North America is Microsoft’s premier technology conference for IT Professionals and Enterprise Developers.

“Our Cyber Security Lab is the first totally integrated system that improves people, processes and procedures in a realistic, operationally focused environment,” stated John Walsh, President of Sypris Electronics. “We improve incident response, reduce damage from a cyber breach, provide a cyber metrics-based method for continuous improvement and achieve cyber resilience.”

The Cyber Security Lab is a system that provides simulation-based applied learning, modeling and simulation, forensics and test/evaluation capabilities. It places individuals and teams in realistic Cyber Defense scenarios to hone their skills and improve performance. Nation-state Governments are selecting and implementing this platform to improve their cyber maturity and stay ahead of global cyber threats.

“Our technology, content and simulations are continually refreshed through a consortium of best-of-breed partners that we call a Cyber Pack,” added Brian Maguire, Vice President of Cyber Operations and Analytics at Sypris Electronics.

Sypris is a global, integrated systems solutions provider. Our ruggedized electronic encryption products, cybersecurity operations and analytics products, consulting and training services, and electronic manufacturing capabilities are aligned through the best people, practices, and technologies to continually exceed customer expectations. Sypris consistently promotes an agile, innovative culture and a state of the art solution set by strategically partnering with leading‐edge technology companies, agencies and universities. With 50 years of experience, Sypris is proud to develop, manufacture and integrate leading technologies that secure our global partners’ interests. For more information, please visit www.sypriselectronics.com.

Monday, May 12th, 2014 Uncategorized Comments Off

(OVRL) Executive Recognized for Leadership Excellence

Overland’s Global VP of HR Carol Dixon Honored at Northern California HR Symposium

SAN DIEGO, CA–(May 12, 2014) – Overland Storage (NASDAQ: OVRL), a trusted global provider of unified data management and data protection solutions across the data lifecycle, today announced that Global Vice President of Human Resources Carol R. Dixon has been recognized by The Northern California HR Symposium for extraordinary achievement in HR leadership.

The esteemed HR Leadership Award is presented to a proven HR trailblazer in the Bay Area who articulates a clear organizational vision; demonstrates HR strategic leadership and business input; impacts corporate culture and empowers change; and has exhibited HR excellence throughout the years, influencing the industry and driving social responsibility.

“I am delighted that Carol has been acknowledged by the HR Symposium for her achievements in advancing the practice of Human Resources,” said Overland’s CEO and President Eric Kelly. “In her HR leadership role for Overland, Carol continues to actively partner with our executive leadership team to develop the processes, systems and tools required to achieve HR operational excellence.”

As vice president of global human resources for Overland Storage, Dixon reports directly to Eric Kelly and is responsible for the ongoing development and implementation of overall HR strategy for the organization. She leads all aspects of human resources management worldwide, including talent acquisition and talent management strategies; organizational development; workforce planning; compensation and benefits; training and workforce development; legal compliance; and employee services.

The 2014 HR Symposium award ceremony will take place on May 13, 2014, at the Santa Clara Convention Center. More than 600 HR professionals are expected to attend the event which highlights HR excellence in Silicon Valley. Headlining this year’s HR Symposium is Jeff Weiner, the CEO of LinkedIn.

About Overland Storage
Overland Storage is a trusted global provider of unified data management and data protection solutions across the data lifecycle. The Company delivers one of the most extensive and complementary product portfolios and service offerings in the industry. By providing an integrated range of technologies and services for primary, nearline, offline, and archival data storage, Overland Storage and Tandberg Data, a wholly owned subsidiary of Overland, make it easy and cost effective to manage different tiers of information over the data lifecycle, whether distributed data is across the hall or across the globe. Overland Storage and Tandberg Data solutions are available through a select network of value-added resellers and system integrators. For more information on Overland Storage, visit www.overlandstorage.com. For more information on Tandberg Data, visit www.tandbergdata.com.

Overland Storage, the Overland logo and Tandberg Data are trademarks or registered trademarks of Overland Storage, Inc. that may be registered in some jurisdictions. All other trademarks are the property of their respective owners.

PR Contact:

Overland Storage
Susan Merriman
303 417-7110
smerriman@tandbergdata.com

Monday, May 12th, 2014 Uncategorized Comments Off

(GOMO) Announces the Appointment of New Independent Directors

GUANGZHOU, China, May 12, 2014 — Sungy Mobile Limited (Nasdaq:GOMO) (“Sungy Mobile” or the “Company”), a leading provider of mobile internet products and services globally with a focus on applications and mobile platform development, today announced that its board of directors (the “Board”) has appointed Mr. Yong Chen and Mr. Gang Zhao as independent directors, effective May 12, 2014. Mr. Yong Chen will succeed Mr. Zhi Zhu in his role as the chairman of the compensation committee of the Board and as a member of the audit committee of the Board. Mr. Gang Zhao will replace Mr. Zhi Zhu in his role as a member of the corporate governance and nominating committee of the Board and replace Mr. Yuqiang Deng in his role as a member of the compensation committee of the Board. Additionally, Mr. Zhi Zhu and Mr. David Ying Zhang have voluntarily resigned from the Board, effective May 12, 2014.

Mr. Yong Chen is a seasoned mobile internet professional with extensive leadership experience with Chinese leading TMT companies in the areas of operation, product, and user management. Mr. Chen currently serves as the vice president and chief operating officer of Tianya Club, the leading internet forum for blogging and BBS in China. In this position, Mr. Chen is responsible for overseeing core business operations including mobile, online games, travel, BBS, and content management. Previously, he served as the regional manager at Great Wall Broadband Network Service, a broadband service operator with extensive network resources, and managed business operations in Haikou and Guangzhou. Mr. Chen received a bachelor’s degree in Computer Science and Communications from Zhejiang University in China.

Mr. Gang Zhao currently is the general manager of Anguanjia, a leading independent third party mobile security service provider in China. Under Mr. Zhao’s leadership, Anguanjia achieved a number of outstanding milestones including the introduction of several innovative products such as “Safe Management”, “Mobile Cloud Security”, and “Anquan Open Platform”. Prior to this role, Mr. Zhao served in several managerial roles, responsible for operations management and product development in a number of Chinese leading TMT companies. Mr. Zhao received a bachelor’s degree in Computer Science and Technology from Peking University in China.

Mr. Yuqiang Deng, Chairman and Chief Executive Officer of Sungy Mobile, stated, “We are excited to welcome Mr. Chen and Mr. Zhao to our Board. Their wealth of China TMT industry experience is a great asset, and will bring new perspectives and expertise to the Board’s discourse, enhancing the strength of our executive team and ability to maximize shareholder value. I would also like to take this time to thank Mr. Zhu and Mr. Zhang for their significant contributions to Sungy Mobile’s success. We are very appreciative of your dedication and service to our firm and wish you all the best going forward.”

About Sungy Mobile Limited

Sungy Mobile Limited is a leading provider of mobile internet products and services globally with a focus on applications and mobile platform development. Sungy Mobile’s platform product, GO Launcher EX, manages apps, widgets and functions on Android smartphones and serves as users’ first entry point to their phones; it is the mobile access point from which many Android users are able to find new and innovative ways to customize their experience, download apps and interact with their mobile devices every day. For more information, please visit http://www.sungymobile.com.

Safe Harbor Statements

This press release contains forward-looking statements. These statements constitute forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the business outlook and quotations from management in this announcement contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Further information regarding these and other risks is included in Sungy Mobile’s filings with the U.S. Securities and Exchange Commission. Sungy Mobile does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

CONTACT: Investor Relations Contact:

         ICR, LLC
         Qiyiana Tian
         Tel: +1-646-417-5388
         Email: IR@sungymobile.com

Monday, May 12th, 2014 Uncategorized Comments Off

(CPST) Names Richard B. Lewis as Vice President, Operations

CHATSWORTH, Calif., May 12, 2014 — Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST), the world’s leading clean technology manufacturer of microturbine energy systems, announced today that it has named Richard B. Lewis to the position of Vice President, Operations effective May 12, 2014.

“Richard will be responsible for all manufacturing operations and facilities at Capstone. He brings with him a wealth of experience and solid accomplishments through a variety of leadership positions directly associated with this critical component of our business,” said Darren Jamison, President and Chief Executive Officer of Capstone.

Mr. Lewis has over 29 years’ experience in manufacturing, global supply chain, and logistics as well as quality assurance and program management, with proven strengths in strategic planning and lean enterprise implementation for companies on rapid growth trajectories. He brings a track record of successfully building world class organizations that deliver extraordinary results. He is adept at defining winning supply chain solutions and motivating high performance teams to consistently accomplish challenging performance objectives. Mr. Lewis holds a Bachelor of Arts in Economics from the University of Massachusetts.

In addition to the other terms of his employment arrangement with Capstone, Mr. Lewis received a grant of equity securities effective upon the date of commencement of his employment. Mr. Lewis received options to purchase 250,000 shares of the common stock of the Company. Conditioned on his continued employment, the options will vest 25% after one year and, thereafter, will vest pro rata each month over the next 36 months. The exercise price of the options granted to Mr. Lewis will be the fair market value of Capstone’s common stock on the date of the grant, which is the closing price per share as reported on the Nasdaq Global Market on May 12, 2014. The options expire 10 years from the date of grant. Mr. Lewis will also receive a grant of 62,500 restricted stock units that vest 25% after each of the first four years of service.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST) is the world’s leading producer of low-emission microturbine systems and was the first to market commercially viable microturbine energy products. Capstone Turbine has shipped approximately 7,000 Capstone Microturbine systems to customers worldwide. These award-winning systems have logged millions of documented runtime operating hours. Capstone Turbine is a member of the U.S. Environmental Protection Agency’s Combined Heat and Power Partnership, which is committed to improving the efficiency of the nation’s energy infrastructure and reducing emissions of pollutants and greenhouse gases. A UL-Certified ISO 9001:2008 and ISO 14001:2004 certified company, Capstone is headquartered in the Los Angeles area with sales and/or service centers in the New York Metro Area, United Kingdom, Mexico City, Shanghai and Singapore.

The Capstone Turbine Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6212

“Capstone” and “Capstone MicroTurbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT: Capstone Turbine Corporation
         Investor and investment media inquiries:
         818-407-3628
         ir@capstoneturbine.com

Monday, May 12th, 2014 Uncategorized Comments Off

(TSRO) Final Phase 3 Trial of Rolapitant Primary and All Secondary Endpoints

Achieved Primary Endpoint of Complete Response (CR) in the Delayed Period (24 to 120 Hours) Following Initiation of Chemotherapy
Achieved Key Secondary Endpoints of CR in the Acute and Overall Periods
Achieved All Secondary Endpoints, Including No Significant Nausea
Adverse Event Profile Consistent with Earlier Clinical Trials
New Drug Application (NDA) Submission to U.S. FDA On Track for Mid-2014

WALTHAM, Mass., May 12, 2014 — TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced positive top-line results from the third and final Phase 3 trial of rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV). The rolapitant arm in this trial, which enrolled patients receiving cisplatin-based, highly emetogenic chemotherapy (HEC), successfully achieved statistical significance over the standard therapy arm for the primary and all secondary endpoints. The adverse event profile for rolapitant remains consistent with that seen in previous clinical studies.

“In our view, these results describe a differentiated profile for rolapitant. We are enthusiastic about the potential for this product candidate, with a profile that may include an extended half life; convenient, single-dose oral and intravenous formulations; and a lack of CYP3A4-mediated drug interactions,” said Mary Lynne Hedley, Ph.D., president of TESARO. “We are very pleased with these data, and we look forward to presenting the detailed results of this trial, together with the results of our prior to Phase 3 trials, at the upcoming American Society of Clinical Oncology (ASCO) annual meeting.”

The third Phase 3 study of rolapitant was an international, multicenter, randomized, double-blind, active-controlled study that enrolled 532 cancer patients receiving cisplatin-based chemotherapy regimens at a dose equal to or greater than 60 mg/m². Patients were randomized to receive either control, which consisted of a 5-HT₃ receptor antagonist plus dexamethasone, or 200 milligrams of oral rolapitant plus control. The rolapitant arm in this study successfully achieved statistical significance over the control arm for the primary endpoint of complete response (CR) in the delayed phase of CINV. In addition, the rolapitant arm also successfully achieved statistical significance over the control arm for the key secondary endpoints of CR in the acute (0 to 24 hour) and overall (0 to 120 hour) phases of CINV, for the secondary endpoint of no significant nausea, and for all other secondary endpoints.

Safety and tolerability data for patients who received rolapitant were similar to the results for those who received control, and were consistent with earlier clinical studies. The most frequently observed adverse events were balanced across treatment arms and included fatigue, constipation and loss of appetite.

Preparations continue in support of a submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in mid-2014. The oral rolapitant NDA will include data from one Phase 3 study in patients receiving moderately emetogenic chemotherapy (MEC), in addition to one Phase 2 and two Phase 3 trials in patients receiving cisplatin-based, highly emetogenic chemotherapy (HEC), including the trial announced today. The top-line results of the Phase 3 trial in MEC and the prior Phase 3 trial in HEC were previously announced by TESARO in December 2013.

Rolapitant is an investigational agent and, as such, has not been approved by the U.S. FDA or any regulatory agencies.

About Rolapitant

Rolapitant is a potent and selective neurokinin-1 (NK-1) receptor antagonist with an extended plasma half-life that is being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). NK-1 receptors are highly concentrated in the brain and bind the neurokinin substance P. Activation of NK-1 receptors plays a central role in nausea and vomiting induced by emetogenic stimuli, including certain cancer chemotherapies. NK-1 receptor antagonists have been demonstrated to improve the management of nausea and vomiting experienced by cancer patients undergoing chemotherapy. The safety and tolerability of single and repeat doses of rolapitant have been assessed in more than 2,500 healthy volunteers and patients. Rolapitant is being developed both in oral and intravenous formulations. TESARO licensed exclusive rights for the development, manufacture, commercialization and distribution of rolapitant from OPKO Health, Inc.

About Chemotherapy-Induced Nausea and Vomiting (CINV)

CINV is estimated to afflict over 70% of cancer patients undergoing chemotherapy and, if not prevented, may possibly result in a delay or even discontinuation of chemotherapy treatment. Prolonged nausea and vomiting may result in unwanted weight loss, dehydration and malnutrition, as well as hospitalization.

About TESARO

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the outcome of clinical trials, the timing of the availability of data from ongoing clinical trials, expectations for the timing of regulatory submissions and regulatory approvals, and other matters that could affect the availability or commercial potential of rolapitant, such as the availability of an intravenous formulation of the product candidate. Rolapitant is an investigational agent and, as such, has not been approved by any regulatory agencies. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO’s annual report on Form 10-K for the year ended December 31, 2013 and quarterly report on Form 10-Q for the quarter ended March 31, 2014.

CONTACT: Investor/Media Contact:
         Jennifer Davis
         Sr. Director, Corporate Development & Investor Relations
         +1.781.325.1116 or jdavis@tesarobio.com

Monday, May 12th, 2014 Uncategorized Comments Off

(IRDM) Announces Pricing of Common Stock and Series B Preferred Stock

MCLEAN, Va., May 9, 2014 — Iridium Communications Inc. (Nasdaq:IRDM) (“Iridium”) today announced the pricing of its offering of 7,377,050 shares of its common stock at a price to the public of $6.10 per share and 500,000 shares of its new 6.75% series B cumulative perpetual convertible preferred stock at a price to the public of $250 per share. The gross proceeds to Iridium from the offerings are expected to be approximately $170 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Iridium. Both offerings are expected to close on or about May 14, 2014. In connection with the common stock offering, Iridium also granted to the underwriters a 30-day option to purchase up to 1,106,558 additional shares of common stock at the public offering price to cover over-allotments, if any.

Raymond James, Deutsche Bank Securities and William Blair are acting as joint book-running managers for the common stock offering. Deutsche Bank Securities and Raymond James are acting as joint book-running managers for the preferred stock offering and Canaccord Genuity and Société Générale are acting as co-managers.

The offerings are being made only by means of a base prospectus and separate prospectus supplements for each offering, all of which are part of Iridium’s effective shelf registration statement that has been filed with the Securities and Exchange Commission (the “SEC”). Copies of either or both prospectus supplements and the accompanying base prospectus for either or both offerings, may be obtained at the SEC’s website at http://www.sec.gov or from Raymond James & Associates, Inc., by telephone at 1-800-248-8863 or by email at prospectus@raymondjames.com or Deutsche Bank Securities Inc., by telephone at 1-800-503-4611 or by email at prospectus.CPDG@db.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be a sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Iridium Communications Inc.

Iridium^® is the only mobile voice and data satellite communications network that spans the entire globe. Iridium enables connections between people, organizations and assets to and from anywhere, in real time. Together with its ecosystem of partner companies, Iridium delivers an innovative and rich portfolio of reliable solutions for markets that require truly global communications. The company has a major development program underway for its next-generation network – Iridium NEXT. Iridium Communications Inc. is headquartered in McLean, Va., U.S.A., and its common stock trades on the NASDAQ Global Select Market under the ticker symbol IRDM. For more information about Iridium products, services and partner solutions, visit www.iridium.com.

Forward-Looking Statements

Statements in this press release that are not purely historical facts may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties such as those, among others, relating to Iridium’s expectations regarding the closing of Iridium’s public offerings. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as risks and uncertainties associated with Iridium’s business and finances in general. Other factors that could cause actual results to differ materially from those indicated by the forward-looking statements include those factors listed under the caption “Risk Factors” in the company’s Form 10-Q for the quarter ended March 31, 2014, filed with the SEC on May 1, 2014, as well as other filings Iridium makes with the SEC from time to time. There is no assurance that Iridium’s expectations will be realized. If one or more of these risks or uncertainties materialize, or if Iridium’s underlying assumptions prove incorrect, actual results may vary materially from those expected, estimated or projected. Iridium’s forward-looking statements speak only as of the date of this press release, and Iridium undertakes no obligation to update forward-looking statements.

CONTACT: Investor Contact:

         Steve Kunszabo
         Iridium Communications Inc.
         +1 (703) 287-7570
         steve.kunszabo@iridium.com

         Press Contact:

         Diane Hockenberry
         Iridium Communications Inc.
         +1 (703) 287-7421
         diane.hockenberry@iridium.com

Friday, May 9th, 2014 Uncategorized Comments Off

(PBMD) CVac™ Granted Fast Track Designation by FDA

SYDNEY, AUSTRALIA–(May 9, 2014) – Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (“Prima”) is pleased to announce today that the United States Food and Drug Administration (“FDA”) granted Fast Track Designation to the CVac clinical development program at Prima. This program is intended to improve overall survival in patients with relapsed platinum-sensitive epithelial ovarian cancer who enter a second complete remission. Prima will work closely with the FDA in accelerating its development program for CVac to potentially bring this treatment option to patients in the U.S.

Matthew Lehman, Prima’s CEO said: “This designation is an important milestone for Prima. The FDA decision is in recognition of the serious nature of ovarian cancer and the clear unmet medical need to develop new treatments for relapsed platinum-sensitive ovarian cancer in remission. Building from our CAN-003 trial data, which indicated an improvement in progression-free survival in this patient population, we look forward to accelerating our recently commenced CAN-004-B trial to establish overall survival advantages of CVac as soon as possible.”

Established under the FDA Modernization Act of 1997, Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track designation is reserved for therapies that attempt to treat diseases where no other therapy is available or where the Fast Track therapy shows some advantages over available therapy.

Fast Track designation confers some or all of the following benefits: more frequent meetings with FDA to discuss the drug’s development plan and ensure collection of appropriate data needed to support drug approval, more frequent written correspondence from FDA about such things as the design of the proposed clinical trials and use of biomarkers, eligibility for Accelerated Approval and Priority Review, if relevant criteria are met, and Rolling Review, which means that a drug company can submit completed sections of its Biological License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the application is completed before the entire application can be reviewed.

This Fast Track status granted by the FDA for CVac comes in addition to the “Orphan Drug Designation” previously granted by the FDA in September 2010. Orphan Drug Designation is intended to provide incentives to encourage companies to pursue cures and treatments for rare diseases by providing major benefits during the product commercialisation process. Key incentives include the exclusive rights to the cure or treatment for a specific condition for 7 years post the approval to commercially market CVac and waiving of FDA fees.

CVac has an additional designation to facilitate its delivery to patients. In June 2010 CVac was granted “Orphan Medicinal Product Designation” by the European Medicines Agency (EMA). This designation also provides major benefits during product commercialisation. Key incentives include the exclusive rights to the cure or treatment for a specific condition for 10 years post the approval to commercially market CVac and the provision of tax reductions.

About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima’s lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au

For further information please contact:

USA Investor/Media:
Adam Holdsworth
ProActive Capital
+1 (646) 862 4607
Email Contact

Australia Investor/Media:
Mr Matthew Gregorowski
Citadel Communications
+61 (0) 422 534 755
Email Contact

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact

Friday, May 9th, 2014 Uncategorized Comments Off

(RGLS) to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference

LA JOLLA, Calif., May 9, 2014 — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus, will present a company overview at the Bank of America Merrill Lynch 2014 Healthcare Conference on Thursday, May 15, 2014 at 12:00 p.m. PDT. The conference is being held at the Encore at the Wynn Las Vegas.

The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of the Company’s website at www.regulusrx.com. A replay of the webcast will be archived on the Company’s website following the presentation date.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. Regulus has a well-balanced microRNA therapeutics pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases. Specifically, Regulus is developing RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, and RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection. Regulus’ commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec focused on microRNA biomarkers. In addition, the Company has established Regulus microMarkers™, a research and development division focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus’ expectations regarding future therapeutic and commercial potential of Regulus’ business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus’ programs are described in additional detail in Regulus’ SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Friday, May 9th, 2014 Uncategorized Comments Off

(ANCI) Closes $2 Million Private Placement

American CareSource Holdings (NASDAQ: ANCI) announced today that it has closed a non-brokered private placement of 1 million shares at a price of $2 per share for total proceeds of $2 million. The placement was fully subscribed and was a private offering under the applicable securities laws.

“We are delighted to have closed this private placement, the proceeds of which we are immediately investing in our urgent care strategy. It exemplifies the confidence and enthusiasm there is for our entry into a quickly expanding market in which the company will distinguish itself as the high-quality, patient-centric provider of conveniently available affordable urgent care,” said Dr. Richard W. Turner, the company’s Chairman and CEO.

The company recently announced its definitive agreement to acquire substantially all of the assets of CorrectMed, including two urgent care centers in the Atlanta metro area. The proceeds from the private placement will facilitate the closing of the transaction.

Subsequent to the private placement, the company will have approximately 6.7 million common shares outstanding.

About American CareSource Holdings, Inc.

American CareSource Holdings is the first national, publicly traded ancillary care network services company. The company offers a comprehensive national network of more than 4,800 ancillary service providers at more than 33,300 sites through its subsidiary, Ancillary Care Services. ACS provides ancillary health care services through its network that offers cost-effective adjunctive support that delivers urgent and primary care through a network of free-standing centers as well as its support of physician- and hospital-based services. These providers offer services in 31 categories, including laboratories, dialysis centers, free-standing diagnostic imaging centers, infusion centers, long-term acute care centers, home health services and non-hospital surgery centers, as well as durable medical equipment. The company’s ancillary network and management provide a complete outsourced solution for a wide variety of health care payors and plan sponsors, including self-insured employers, indemnity insurers, PPOs, HMOs, third-party administrators and both federal and local governments. For additional information, please visit www.anci-care.com.

Friday, May 9th, 2014 Uncategorized Comments Off

(MTRX) Awarded Over $100 Million in Terminal Expansion Contracts

TULSA, Okla., May 9, 2014 — Matrix Service Company (Nasdaq:MTRX) announced today Enbridge Energy has awarded terminal expansion contracts in excess of $100 million to Matrix subsidiaries.

Matrix subsidiaries will provide engineering, fabrication, and construction services associated with aboveground storage tanks as part of Enbridge’s terminal expansion program. All site, civil, tank design and fabrication, erection, testing and coatings services related to the new storage tanks will be completed at Enbridge’s Stockbridge and Superior terminals.

John Hewitt, CEO of Matrix Service Company stated “Enbridge is a very important customer and we are pleased to be selected for their expansion projects in their Stockbridge and Superior Terminals. We look forward to delivering safe and successful projects for Enbridge.”

About Matrix Service Company

Matrix Service Company provides engineering, fabrication, construction and repair and maintenance services to the Electrical Infrastructure, Oil Gas & Chemical, Storage Solutions and Industrial markets.

The Company is headquartered in Tulsa, Oklahoma, with regional operating facilities throughout the United States and Canada.

This release contains forward-looking statements that are made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are generally accompanied by words such as “anticipate,” “continues,” “expect,” “forecast,” “outlook,” “believe,” “estimate,” “should” and “will” and words of similar effect that convey future meaning, concerning the Company’s operations, economic performance and management’s best judgment as to what may occur in the future. Future events involve risks and uncertainties that may cause actual results to differ materially from those we currently anticipate. The actual results for the current and future periods and other corporate developments will depend upon a number of economic, competitive and other influences, including those factors discussed in the “Risk Factors” and “Forward Looking Statements” sections and elsewhere in the Company’s reports and filings made from time to time with the Securities and Exchange Commission. Many of these risks and uncertainties are beyond the control of the Company, and any one of which, or a combination of which, could materially and adversely affect the results of the Company’s operations and its financial condition. We undertake no obligation to update information contained in this release.

CONTACT: Matrix Service Company
         Kevin S. Cavanah
         Vice President and CFO
         T: 918-838-8822
         Email:kcavanah@matrixservicecompany.com

Friday, May 9th, 2014 Uncategorized Comments Off

(FBMI) & Mercantile Bank Corp. Merger Receives Full Regulatory Approval

GRAND RAPIDS, Mich., May 8, 2014 — Mercantile Bank Corporation (NASDAQ: MBWM) (“Mercantile”) and Firstbank Corporation (NASDAQ: FBMI) (“Firstbank”) announced today that all regulatory approvals for their proposed merger, announced on August 15, 2013, have been received. Mercantile and Firstbank shareholders previously approved the merger in December 2013. Subject to the satisfaction of customary closing conditions, the merger is expected to be completed as of June 1, 2014. The combined companies will operate as Mercantile Bank Corporation.

“We are pleased that, after an extensive and meticulous regulatory review, we have obtained approval to complete this transformational merger with Firstbank Corporation,” said Michael Price, Mercantile President, Chairman and Chief Executive Officer. “This merger creates a powerhouse Michigan-based community bank holding company that is well positioned for future growth opportunities. This approval validates our history of community involvement and outstanding performance under the Community Reinvestment Act, and follows a thorough analysis of our lending practices.”

Tom Sullivan, Firstbank President and Chief Executive Officer, said, “With these regulatory hurdles behind us, we are thrilled to move forward with bringing the benefits of this merger to both Firstbank and Mercantile shareholders, customers and communities.”

About Mercantile Bank Corporation
Based in Grand Rapids, Michigan, Mercantile Bank Corporation is the bank holding company for Mercantile Bank of Michigan. Founded in 1997 to provide banking services to businesses, individuals and governmental units, the Bank differentiates itself on the basis of service quality and the expertise of its banking staff. Mercantile has assets of $1.4 billion and seven full-service banking offices in Grand Rapids, Holland and Lansing, Michigan.

About Firstbank Corporation
Firstbank Corporation, headquartered in Alma, Michigan, is a bank holding company using a community bank local decision-making format with assets of $1.5 billion and 46 banking offices serving Michigan’s Lower Peninsula.

Forward-Looking Statements
This press release contains comments or information that constitute forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995) that are based on current expectations that involve a number of risks and uncertainties. These forward looking statements are subject to a number of factors and uncertainties which could cause Mercantile, Firstbank, or the combined company’s actual results and experience to differ from the anticipated results and expectations expressed in such forward looking statements. Forward looking statements speak only as of the date they are made and neither Mercantile nor Firstbank assumes any duty to update forward looking statements. These forward-looking statements include, but are not limited to, statements about (i) the expected benefits of the transaction between Mercantile and Firstbank, including future financial and operating results, accretion and earn-back, cost savings, enhanced revenues, long term growth, and the expected market position of the combined company that may be realized from the transaction, and (ii) Mercantile’s and Firstbank’s plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts. Other statements identified by words such as “expects,” “well-positioned,” “opportunity,” “future,” “will,” or words of similar meaning generally are intended to identify forward-looking statements. These statements are based upon the current beliefs and expectations of Mercantile’s and Firstbank’s management and are inherently subject to significant business, economic and competitive risks and uncertainties, many of which are beyond their respective control. In addition, these forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Actual results may differ materially from those indicated or implied in the forward-looking statements. Although Mercantile and Firstbank have signed an agreement, there is no assurance that they will complete the proposed merger. The merger agreement will terminate if any conditions to closing are not satisfied. There is no assurance that the due diligence process would identify all risks associated with the transaction. Additional information concerning risks is contained in Mercantile’s and Firstbank’s most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, recent Current Reports on Form 8-K and other SEC filings.

Thursday, May 8th, 2014 Uncategorized Comments Off

(ALDX) Data on Lead Candidate NS2 to be Presented at Society for Investigative Dermatology

Results Suggest Novel Approach to Treating Dry Skin and Dry Eye Diseases

BURLINGTON, Mass., May 8, 2014 — Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that new data supporting its lead product candidate, NS2, which is designed to trap aldehydes, will be presented as an abstract poster at the Society for Investigative Dermatology (SID) 2014 Annual Meeting, being held May 7, 2014 through May 10, 2014, in Albuquerque, New Mexico.

The study, titled “NS2, a novel aldehyde trap, decreases aldehyde levels in dry skin and eye models” (Abstract LB793), will be presented during Poster Session I on Thursday, May 8, 2014 from 10am – 12pm (MT) in the NE Exhibit Hall of the Albuquerque Convention Center. In addition, the abstract was selected for discussion at the invitation-only Academic/Industry Session that follows the Academic-Industry Partnership Project during the Satellite Symposium being held on Thursday, May 8 at 12pm – 2 pm (MT).

Researchers studied the effect of dry conditions on inducing malondialdehyde (MDA) levels – which have been shown to be elevated in a variety of inflammatory skin and eye diseases – in human skin and eye tissue and the activity of NS2 in reducing levels of MDA generated by dry conditions. The study found that topical application of NS2 cream to three-dimensional human skin equivalents lowered MDA levels (measured by thiobarbituric acid reactive substances, or TBARS, assay) induced by dry skin conditions, and topical application of NS2 eye drops to three-dimensional human cornea-like tissue lowered MDA levels induced by dry eye conditions.

Researchers concluded that in topical dermatologic and eye drop formulations, NS2 has significant aldehyde trapping activity in human dermal and ocular tissue subjected to dry conditions and that topically applied NS2 could be a safe and effective treatment for diseases characterized by dry tissue. Researchers also concluded that dry conditions induce aldehyde generation in human dermal and ocular tissue and that the cream vehicle used for NS2 formulations and NS2 creams between 0.05-0.1% are unlikely skin irritants when topically applied twice a day to human skin equivalents with 12 hours between applications.

NS2 is an aldehyde-binding small molecule based on an innovative platform technology created to bind and trap free aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases, and are thought to impair the formation of moisture barriers in tissue. By decreasing aldehyde load, NS2, in pre-clinical studies, has demonstrated multiple mechanisms of action, including generating an anti-inflammatory response, legion healing, reduction of fibrosis, and protection of a lipid critical to dermal tissue moisture barriers and ocular tear integrity. As a product candidate, NS2 is currently being evaluated to address two underserved skin and eye diseases, Sjögren-Larsson Syndrome and acute anterior uveitis.

Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, “We are excited to present the findings of our recent studies at this year’s SID Annual Meeting. These data demonstrate that our lead product candidate NS2 has the ability to trap free aldehydes and may thereby protect specific lipids critical to preserving moisture in the skin and eye. Given the results that we have seen, we believe that NS2 can be a viable and effective therapeutic option for patients who suffer from dry skin or dry eye conditions.”

About NS2

NS2, a product candidate that is designed to trap and allow for disposal of free aldehydes, is under development for the treatment of Sjögren-Larsson Syndrome (SLS), a rare disease caused by mutations in an enzyme that metabolizes fatty aldehydes, and acute anterior uveitis, a rare disease characterized by severe inflammation and pain in the anterior eye.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc, is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s plans for its product candidates. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward- looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Aldeyra’s forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval of Aldeyra’s product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra’s product candidates; the size and growth of the potential markets for Aldeyra’s product candidates and the ability to serve those markets; Aldeyra’s expectations regarding Aldeyra’s expenses and revenue, the sufficiency of Aldeyra’s cash resources and needs for additional financing; Aldeyra’s ability to attract or retain key personnel; and other factors that are described in the “Risk Factors” section of Aldeyra’s final prospectus filed under Rule 424(b)(4) with the Securities and Exchange Commission in connection with Aldeyra’s initial public offering. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

CONTACT: Investor Contact:
         David Burke/Lee Roth
         The Ruth Group
         Tel: 646-536-7009/7012
         dburke@theruthgroup.com
         lroth@theruthgroup.com

Thursday, May 8th, 2014 Uncategorized Comments Off

(CHTP) Lundbeck to Acquire Chelsea Therapeutics

By acquiring Chelsea Therapeutics, Lundbeck gains the rights to Chelsea Therapeutics’ recently FDA-approved product, NORTHERA^TM (droxidopa), which is expected to be launched later in 2014
NORTHERA is an orphan neurology opportunity with strong commercial and strategic fit with Lundbeck’s existing U.S. neurology franchise
Chelsea stockholders are entitled to USD 6.44 per share in cash and CVRs that may pay up to USD 1.50, for a total potential consideration of up to USD 7.94 per share, or USD 658 million on a fully diluted basis
The offer provides Chelsea stockholders with immediate and certain upfront value as well as participation in potential commercial upside of NORTHERA
The transaction is expected to be cash accretive to Lundbeck in 2015 and earnings accretive in 2016

VALBY, Denmark and CHARLOTTE, N.C., May 8, 2014 — H. Lundbeck A/S (Lundbeck) and Chelsea Therapeutics International, Ltd. (Chelsea) (Nasdaq:CHTP) today announced that the companies have entered into a definitive agreement under which Lundbeck will acquire Chelsea.

Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Chelsea, whereby Chelsea stockholders will be offered an upfront payment and contingent value rights (CVRs), representing a total potential consideration of up to USD 7.94 per share, or USD 658 million (approximately DKK 3.54 billion) on a fully diluted basis. The total potential consideration represents an attractive premium of 59% over the closing price of Chelsea shares on 7 May 2014.

Consideration includes USD 6.44 per share in cash, or approximately USD 530 million (approximately DKK 2.8 billion) on a fully diluted basis, as well as CVRs that may pay up to a total of an additional USD 1.50 upon achievement of certain commercial milestones related to NORTHERA’s commercial performance in the period 2015-2017. The proposed upfront per-share price represents a premium of approximately 29% over Chelsea’s closing price of USD $5.00 on 7 May 2014.

The terms of the CVR payments reflect the parties’ agreement over the sharing of potential economic upside benefits from certain future net sales of NORTHERA as described in the CVR agreement and do not necessarily reflect anticipated sales of the product. There can be no assurance such levels of net sales will occur or that any or all of the contingent payments will be made.

Lundbeck intends to acquire any shares of Chelsea not tendered into the tender offer through a merger for the same per share consideration as will be payable in the tender offer. The merger will be effected as soon as possible after the closing of the tender offer.

The transaction will allow Lundbeck to leverage its expertise in rare neurologic disorders in the U.S. through the upcoming launch of NORTHERA, which was approved by the FDA on 18 February 2014 for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA that demonstrates symptomatic benefit in adult patients with NOH caused by primary autonomic failure (Parkinson’s disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy. NORTHERA is expected to be launched in the second half of 2014 and will strengthen Lundbeck’s existing neurology franchise in the U.S., which currently includes Onfi, Sabril and Xenazine, and ahead of potential future products like desmoteplase and Lu AE58054 currently in clinical phase III.

“I believe this offer represents an attractive offer to the stockholders of Chelsea and is consistent with Lundbeck’s strategic and disciplined approach to acquisitions,” said Ulf Wiinberg, President & Chief Executive Officer of Lundbeck. He continued, “The proposed strategic acquisition of Chelsea – and the launch of its lead therapy, NORTHERA – aligns with Lundbeck’s core strengths in addressing rare and challenging neurological disorders. As a company committed to people living with brain disorders, we are uniquely positioned to make NORTHERA available to those who need it most.”

Joseph G. Oliveto,President & Chief Executive Officer of Chelsea Therapeutics, stated, “This transaction provides attractive and certain upfront value to our stockholders, and enables them to participate in the potential commercial upside of NORTHERA. Lundbeck’s expertise in commercializing rare disorder CNS products will enable a rapid and successful launch of NORTHERA into the U.S. market and ultimately will provide added benefit to patients suffering from NOH.”

The transaction is expected to be financed by Lundbeck’s existing cash reserves.

The board of directors of Chelsea has unanimously approved the transaction. The transaction is expected to close in the third quarter of 2014, subject to the tender of a majority of Chelsea’s outstanding shares in the tender offer, and the receipt of customary regulatory approvals, including a Hart-Scott-Rodino review in the U.S. The terms and conditions of the tender offer will be described in the tender offer documents, which will be filed with the U.S. Securities and Exchange Commission (SEC).

Moelis & Company acted as financial advisor and Cravath, Swaine & Moore LLP provided legal advice to Lundbeck. Deutsche Bank Securities Inc. and Torreya Capital acted as financial advisors, and Morgan, Lewis & Bockius LLP provided legal advice to Chelsea.

Financial guidance

If closed, this acquisition of Chelsea will impact Lundbeck’s financial guidance for 2014.

While the transaction is not expected to have a material positive impact on revenue in 2014, it is expected to be dilutive to both cash flow and EBIT for the year, and cash flow accretive in 2015. The expected impact on Lundbeck’s profitability in 2014 will depend on the timing of the closing of the transaction. However, on a pro forma basis assuming the transaction is closed on 1 July 2014, Lundbeck expects to incur costs of approximately DKK 500 million in incremental costs related to the acquisition of Chelsea. Approximately half of the costs are related to amortization expenses.

Financial forecast 2014

DKK billion	2013 actual	“Old” 2014 forecast	Potential revision of 2014 forecast
Revenue	15.3	~13.5	~13.5
EBIT	1.6	0.5-1.0	0-0.5

Core EBIT	2.3	1.2-1.7	0.9-1.4

Important information

The tender offer described in this press release has not yet commenced. This press release is for informational purposes only, and it is neither an offer to purchase nor a solicitation of an offer to sell shares of Chelsea’s common stock. At the time any such tender offer is commenced, Lundbeck will cause a new wholly-owned subsidiary, Charlie Acquisition Corp., to file a Tender Offer Statement, containing an offer to purchase, a form of letter of transmittal and other related tender offer documents with the SEC, and Chelsea will file a Solicitation/Recommendation Statement relating to such tender offer with the SEC. Chelsea’s stockholders are strongly advised to read these tender offer materials carefully and in their entirety when they become available, as they may be amended from time to time, because they will contain important information about such tender offer that Chelsea’s stockholders should consider prior to making any decisions with respect to such tender offer. Once filed, stockholders of Chelsea will be able to obtain a free copy of these documents at the website maintained by the SEC at www.sec.gov, or by directing a request to H. Lundbeck A/S, Attention: Investor Relations, Ottiliavej 9, DK-2500 Valby, Copenhagen, Denmark or to the Information Agent for the tender offer which will be named in the Tender Offer Statement. Copies of Chelsea’s filings with the SEC may also be obtained free of charge at the “Investors” section of Chelsea’s website at www.chelseatherapeutics.com.

Conference call

Today at 2.00 pm (CET), Lundbeck will be hosting a conference call for the financial community, find dial-in numbers below. You can listen to the call online at www.lundbeck.com under the investor section.

DK: +45 354 455 83
UK: +44 203 194 05 44
US: +1 855 269 2604

About symptomatic neurogenic orthostatic hypotension (NOH)

It is estimated that 80,000 to 150,000 patients suffer from symptomatic NOH in the U.S. Symptomatic NOH is a chronic disorder that is caused by an underlying neurogenic disorder, such as Parkinson’s disease, multiple system atrophy or pure autonomic failure. Symptoms of NOH may include dizziness, lightheadedness, blurred vision, fatigue, poor concentration, and fainting episodes when a person assumes a standing position. These symptoms can severely limit a person’s ability to perform routine daily activities that require standing or walking for both short and long periods of time ^{i, ii}.

About NORTHERA (droxidopa)

NORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic NOH caused by primary autonomic failure (Parkinson’s disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

The NORTHERA approval was granted under the FDA’s accelerated approval program, which allows for conditional approval of a medicine that fills a serious unmet medical need, provided additional confirmatory studies are conducted. The package insert indicates that effectiveness beyond two weeks of treatment has not yet been demonstrated; therefore the continued effectiveness of NORTHERA in patients should be assessed periodically. A multi-center, placebo-controlled, randomized study, which is designed with the goal of definitively establishing the durability of the clinical benefits of NORTHERA, has been preliminarily agreed to with the FDA.

NORTHERA carries a boxed warning for supine hypertension. The most common ( > 5%) adverse events experienced in controlled studies are headache, dizziness, nausea, hypertension and fatigue. Please see NORTHERA full Prescribing Information for additional Important Safety Information at http://www.chelseatherapeutics.com.

IMPORTANT SAFETY INFORMATION

WARNING: SUPINE HYPERTENSION
See full prescribing information for complete boxed warning. Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA.

CONTRAINDICATIONS

None

WARNINGS AND PRECAUTIONS

Supine Hypertension: NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH, which may increase cardiovascular risk if not well-managed.
Ischemic Heart Disease, Arrhythmias, and Congestive Heart Failure: NORTHERA therapy may exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure.
Hyperpyrexia and Confusion: Postmarketing cases of a symptom complex resembling neuroleptic malignant syndrome (NMS) have been reported in Japan with NORTHERA use. Observe patients carefully when the dosage of NORTHERA is changed or when concomitant levodopa is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics. NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes. The early diagnosis of this condition is important for the appropriate management of these patients.
Allergic Reactions: This product contains FD+C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD+C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

ADVERSE REACTIONS

The most common adverse reactions (greater than 5%) were headache, dizziness, nausea, hypertension, and fatigue.

DRUG INTERACTIONS

Administering NORTHERA in combination with other agents that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans) would be expected to increase the risk for supine hypertension; Dopa-decarboxylase inhibitors may require dose adjustments for NORTHERA.

USE IN SPECIAL POPULATIONS

Clinical experience with NORTHERA in patients with severe renal function impairment (GFR less than 30 mL/min) is limited; There are no adequate and well controlled trials of NORTHERA in pregnant women; Women who are nursing should choose nursing or NORTHERA; The safety and effectiveness of NORTHERA in pediatric patients have not been established; No overall differences in safety or effectiveness were observed between subjects aged 75 years and older, and younger subjects in clinical trials, but greater sensitivity of some older individuals cannot be ruled out.

About Chelsea Therapeutics

Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea acquired global development and commercialization rights to droxidopa (L-DOPS), or NORTHERA, from Dainippon Sumitomo Pharma Co., Ltd. in 2006, excluding Japan, Korea, China and Taiwan. For more information about the Company, visit www.chelseatherapeutics.com.

For the twelve months ended 31 December 2013. Chelsea reported an EPS loss of (USD 0.24). Total operating expenses were USD 16.4 million. R&D expenses were USD 10.4 million. SG&A expenses were USD 6.1 million. As of 31 December 2013, cash and cash equivalents totaled USD 45.3 million.

Lundbeck contacts
Investors:	Media:

Palle Holm Olesen	Mads Kronborg
Vice President, Investor Relations	Director, Media Relations
PALO@lundbeck.com	MAVK@lundbeck.com
+45 36 43 24 26	+45 36 43 30 00

Jens Høyer
Specialist, Investor Relations
JSHR@lundbeck.com
+45 36 43 33 86

Chelsea contacts
Investors:	Media:

David Pitts	Chuck Burgess
Argot Partners	Abernathy MacGregor
david@argotpartners.com	CLB@abmac.com
+1 212-600-1902	+1 212 371 5999

	Liz Micci
	Abernathy MacGregor
	EDM@abmac.com
	+1 212 371 5999

About Lundbeck

H. Lundbeck A/S (LUN.CO) (LUN DC) (HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our development and distribution of pioneering treatments continues to make a difference to people living with brain diseases. Our key areas of focus are alcohol dependence, Alzheimer’s disease, depression/ anxiety, epilepsy, Huntington’s disease, Parkinson’s disease, schizophrenia and stroke.

Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales, and are committed to improving the quality of life of people living with brain diseases. Our pipeline consists of several late-stage development programs and our products are available in more 100 countries. We have research centers in China, Denmark and the United States, and production facilities in China, Denmark, France, Italy and Mexico. Lundbeck generated revenue of DKK 15.3 billion in 2013 (EUR 2.0 billion; USD 2.7 billion).

Lundbeck’s shares are listed on the stock exchange in Copenhagen under the symbol “LUN”. Lundbeck has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol “HLUYY”. For additional information, we encourage you to visit our corporate site www.lundbeck.com.

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as the tender offer and transactions contemplated by the merger agreement, new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for our products, introduction of competing products, our ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, unexpected growth in costs and expenses, the possibility that the transaction may not be consummated or that the expected benefits of the transaction may not materialize as expected, Lundbeck’s and Chelsea’s ability to timely complete the transaction, if at all, or to, prior to the completion of the transaction, if at all, satisfy all closing conditions, the possibility that the merger agreement may be terminated, and the impact of the current economic environment, fluctuations in operating results, market acceptance of NORTHERA, and other risks that are described in Chelsea’s Annual Report on Form 10-K for the year ended December 31, 2013 and in its subsequently filed SEC reports. Neither Lundbeck nor Chelsea undertakes any obligation to update these forward-looking statements except to the extent otherwise required by law.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the United States, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

ⁱ Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21:69-72

ⁱⁱFreeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med 2008;358:615-624. 3. Goldstein DS, Holmes C, Kaufmann H, Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 2004;14:363-368.

Thursday, May 8th, 2014 Uncategorized Comments Off

(TWGP) and ACP Re, Ltd. Announce Amendment to Merger Agreement

Tower Group International, Ltd. (NASDAQ:TWGP) (“Tower”) and ACP Re, Ltd. (“ACP Re”) announced today that they have entered into an amendment to the merger agreement entered into by them on January 3, 2014. The amendment, among other things, (1) reduces the per share consideration to be received by holders of Tower’s common shares in the merger from $3.00 per share to $2.50 per share, (2) reduces the termination fee that Tower would, under certain circumstances, be required to pay to ACP Re in the event of a termination of the merger agreement, (3) extends to November 15, 2014 both the date by which Tower must hold its shareholders meeting to vote on the merger and the deadline for completing the merger before either party can terminate the merger agreement, (4) excludes from the material adverse effect closing condition any continued adverse results of Tower’s operations or deterioration of its financial condition resulting from (a) losses and loss adjustment expenses incurred under new, renewal or in-force insurance and reinsurance related policies, insurance and reinsurance related contracts, and insurance and reinsurance related binders, (b) operating expenses, including acquisition expenses, associated with maintaining Tower’s agency relationships, employees and facilities to operate its business in the ordinary course or (c) the insufficiency of Tower’s loss reserves (including IBNR reserves), (5) also excludes from the material adverse effect closing condition any effect resulting from facts or circumstances disclosed in any of Tower’s previous SEC filings, (6) eliminates the condition that holders of shares representing more than 15% of Tower’s share capital shall not have exercised dissenter’s rights, (7) provides that the closing condition requiring that each of Tower’s U.S. insurance subsidiaries shall have risk based capital that is equal to or exceeds its relevant company action level risk based capital will be deemed to have been satisfied if Tower and its subsidiaries have, on a consolidated basis, sufficient capital that could be reallocated among Tower’s insurance subsidiaries so that such condition could be satisfied and (8) provides that all of Tower’s representations and warranties in the Merger Agreement will be qualified by disclosures made in Tower’s previous SEC filings.

About ACP Re

ACP Re is a Bermuda based reinsurance company. The controlling shareholder of ACP Re is a trust established by the founder of AmTrust Financial Services, Inc., National General Holdings Corporation and Maiden Holdings, Ltd.

About Tower

Tower Group International, Ltd. is a Bermuda-based global diversified insurance and reinsurance holding company and is listed on the NASDAQ Global Select Market under the symbol TWGP. Through our insurance and reinsurance subsidiaries in the U.S. and Bermuda, collectively referred to as Tower Group Companies, we deliver a broad range of commercial, personal and specialty insurance products and services in the U.S. and specialty reinsurance products globally through our distribution and underwriting partners.

For more information, visit Tower’s website at http://www.twrgrpintl.com.

Additional Information and Where to Find It

This communication is not a solicitation of a proxy from any shareholder of Tower. In connection with the merger agreement, Tower filed a preliminary proxy statement with the Securities and Exchange Commission (“SEC”) on February 13, 2014 and intends to file a definitive proxy statement with the SEC and to mail such definitive proxy statement and a form of proxy to Tower’s shareholders when they are completed. Investors and shareholders are urged to read the preliminary proxy statement, the definitive proxy statement and other relevant materials filed with the SEC when they become available because they contain or will contain important information about Tower, ACP Re and the proposed transaction. The preliminary proxy statement, the definitive proxy statement and other relevant materials (when they become available), and any other documents filed by Tower or ACP Re with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, investors and shareholders may obtain free copies of the documents filed by Tower with the SEC by directing a written request to “Investor Relations,” Tower Group International, Ltd., Bermuda Commercial Bank Building, 2nd Floor, 19 Par-la-Ville Road, Hamilton, HM 11, Bermuda, or by email to William E. Hitselberger, Executive Vice President and Chief Financial Officer at bhitselberger@twrgrp.com.

Participants in the Solicitation

The directors, executive officers and other members of management and employees of Tower may be deemed participants in the solicitation of proxies from its shareholders in favor of the proposed transaction. Information concerning persons who may be considered participants in the solicitation of Tower’s shareholders under the rules of the SEC is set forth in public filings filed by Tower with the SEC and will be set forth in the definitive proxy statement when it is filed with the SEC. Information concerning Tower’s participants in the solicitation is contained in Tower’s Proxy Statement on Schedule 14A, filed with the SEC on March 25, 2013.

Cautionary Statement Regarding Forward–Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. This press release and any other written or oral statements made by or on behalf of Tower may include forward-looking statements that reflect Tower’s current views with respect to future events and financial performance. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements can generally be identified by the use of forward-looking terminology such as “may,” “will,” “plan,” “expect,” “project,” “intend,” “estimate,” “anticipate,” “believe” and “continue” or their negative or variations or similar terminology. All forward-looking statements address matters that involve risks and uncertainties. Accordingly, there are or will be important factors that could cause the actual results of Tower to differ materially from those indicated in these statements. Please refer to Tower’s filings with the SEC, including among others Tower’s Annual Report on Form 10-K for the year ended December 31, 2013, for a description of the important factors that could cause the actual results of Tower to differ materially from those indicated in these statements. Forward-looking statements speak only as of the date on which they are made, and Tower undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Risks that could adversely affect the proposed merger include, but are not limited to, the following:

governmental approvals of the merger may not be obtained or adverse regulatory conditions may be imposed in connection with governmental approvals of the merger;
the Board of Directors of Tower may withdraw its recommendation and support a competing acquisition proposal; and
Tower’s shareholders may fail to approve the merger.

The following important factors are among those that could affect the actual outcome of other future events:

changes in our financial strength or credit ratings could impact our ability to write new business, the cost of, and our ability to obtain, capital or our ability to attract and retain brokers, agents and customers;
further decreases in the capital and surplus of our insurance subsidiaries and their ability to meet minimum capital and surplus requirements;
changes in our ability to access our credit facilities or raise additional capital;
the implementation and effectiveness of our capital improvement strategy;
Tower’s ability to continue operating as a going concern;
changes in our ability to meet ongoing cash requirements and pay dividends;
greater frequency or severity of claims and loss activity, including as a result of natural or man-made catastrophic events, than our underwriting, reserving or investment practices anticipate based on historical experience or industry data;
changes in the availability, cost or quality of reinsurance and failure of our reinsurers to pay claims timely or at all;
changes in the availability, cost or quality of reinsurance or retrocessional coverage;
decreased demand for Tower’s insurance or reinsurance products;
increased competition on the basis of pricing, capacity, coverage terms or other factors;
ineffectiveness or obsolescence of Tower’s business strategy due to changes in current or future market conditions;
currently pending or future litigation or governmental proceedings;
developments that may delay or limit Tower’s ability to enter new markets as quickly as it anticipates;
loss of the services of any of Tower’s executive officers or other key personnel;
changes in acceptance of Tower’s products and services, including new products and services;
developments in the world’s financial and capital markets that could adversely affect the performance of Tower’s investments;
the effects of acts of terrorism or war;
changes in general economic conditions, including inflation, interest rates and other factors which could impact Tower’s performance and the performance of Tower’s investment portfolio;
changes in accounting policies or practices;
changes in legal theories of liability under Tower’s insurance policies;
changes in rating agency policies or practices;
declining demand for reinsurance due to increased retentions by cedents and other factors;
a lack of opportunities to increase writings in Tower’s reinsurance lines of business and in specific areas of the reinsurance market;
changes in the percentage of premiums written that Tower cedes to reinsurers;
changes in regulations or laws applicable to Tower, its subsidiaries, brokers or customers, including regulatory limitations and restrictions on the declaration and payment of dividends and capital adequacy standards;
the Bermudian regulatory system, and potential changes thereto;
risks and uncertainties associated with technology, data security or outsourced services that could negatively impact Tower’s ability to conduct its business or adversely impact its reputation;
the effects of mergers, acquisitions or divestitures;
disruptions in Tower’s business arising from the integration of acquired businesses into Tower and the anticipation of potential or pending acquisitions or mergers; and
any changes concerning the conditions, terms, termination, or closing of the merger with ACP Re.

Additional risk factors that may cause outcomes that differ from our expectations or projections are described in various documents filed by Tower with the Securities and Exchange Commission, such as current reports on Form 8–K, and regular reports on Forms 10–K and 10–Q, particularly in “Item 1A, Risk Factors.”

Thursday, May 8th, 2014 Uncategorized Comments Off

Archive for May, 2014

Live Video Webcast on May 21, 2014 at 10:00 AM EDT

Unified Control and Management of New IP Surveillance Cameras Now Part of Ubiquiti’s UniFi Family of Products

2U CTO and CFO nominated in both Tech Council of Maryland and Northern Virginia Technology Council Awards

2U CTO and CFO nominated in both Tech Council of Maryland and Northern Virginia Technology Council Awards

Overland’s Global VP of HR Carol Dixon Honored at Northern California HR Symposium

Results Suggest Novel Approach to Treating Dry Skin and Dry Eye Diseases

TraderPower Featured Companies

Top Small Cap Market News

Recent Posts

Recent Comments

Archives

Categories

Meta